PO5-01-01 The comparison of HER2 low and HER2 0 in ductal carcinoma in situ (DCIS) for breast cancer. Nari Kureyama (1) Maho Kusudo (2) Akira nakakami (2) Rie Komaki (2) Yuka Endo (2) Kazuki Nozawa (3) Ayumi Kataoka (2) Haruru Kotani (4) Akiyo Yoshimura (2) Masaya Hattori (5) Masataka Sawaki (6) Hiroji Iwata (4) (1) Department of Breast Oncology, Aichi Cancer Center Hospital;(2) Aichi Cancer Center Hospital;(3) Aichi Cancer Center Hospital/Department of Breast Oncology, Nagoya, Aichi, Japan;(4) Aichi Cancer Center Hospital, Nagoya, Aichi, Japan;(5) Aichi Cancer Center;(6) Aichi Cancer Center Hospital.

PO5-01-02 A retrospective review of pathological complete response and toxicity rates to a modified version of TCHP (Paclitaxel, Trastuzumab, Pertuzumab, Carboplatin) for HER2 positive breast cancer stage II and III. Carolyn Moloney (1) Maggie Louise O'Connor (1) Caroline O'Leary (1) Aislinn Reilly (1) Simon Barry (1) David O'Reilly (1) Philip Bredin (1) Hadia Paryani (2) David Solaligue (3) Bryan Hennessy (1) Megan Greally (1) Patrick G. Morris (4) (1) Beaumont Hospital;(2) Bons Hospital;(3) Our Lady of Lourdes Hospital, Drogheda, Ireland;(4) Cancer Trials Ireland, Ireland; Beaumont RCSI Cancer Centre, Dublin, Ireland.

PO5-01-03 Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study. Toshiaki Iwase (1) Sridhar Nithya (2) Megumi Kai (3) Jie Willey (4) Wenli Dong (5) Yu Shen (6) Savitri Krishnamurthy (7) Anthony Lucci (8) H. T. Carisa Le-Petross (5) Azadeh Nasrazadani (9) Sadia Saleem (10) Rachel Layman (4) Vicente Valero (11) Debu Tripathy (5) Wendy Woodward (12) Yee Chung Cheng (13) Faina Nakhliis (14) Jennifer Bellon (15) Filipa Lynce (16) Naoto Ueno (17) (1) Translational Cancer Research, University of Hawai'i Cancer Center, Honolulu, HI, USA;(2) Baylor College of Medicine;(3) MD Anderson Cancer Center;(4) The University of Texas MD Anderson Cancer Center;(5) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;(6) UT MD Anderson Cancer Center;(7) MD Anderson cancer center;(8) MD Anderson Cancer Center, Houston, Texas, United States;(9) Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;(10) MD Anderson Cancer Institute;(11) Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Bellaire, Texas, United States;(12) UT MD Anderson Cancer Center, Houston, Texas, United States;(13) Medical College of Wisconsin;(14) Dana-Farber Cancer Institute;(15) DFCI/BWH, Boston, Massachusetts, United States;(16) Dana-Farber Cancer Institute, Boston, Massachusetts, United States;(17) University of Hawai'i Cancer Center, Honolulu, HI, USA.

PO5-01-04 HER2 Amplification Level and Focal/Broad Region Size as Predictors of Treatment Response in Neoadjuvant Chemotherapy and Anti-HER2 Therapy for HER2-Positive Breast Cancer. Ning Liao (1) Guochun Zhang (2) Xinze Lv (3) Kai Li (2) Ting Hou (4) Zhou Zhang (4) (1) Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China;(2) Department of Breast Cancer, the General Surgical Department, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China;(3) Burning Rock Biotech, Guangzhou, China;(4) Burning Rock Biotech.

PO5-01-05 An Open-label, Single-center Study Assessing the Efficacy of PH-based Regimen as Neoadjuvant Therapy for HER2-positive Early-stage Breast Cancer: Integrating Genomic Features and

(1) Shaare Zedek Medical Center; (2) Rabin Medical Center, Beilinson Hospital, Davidoff Center; (3) Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tiqwa, and the Sackler Faculty of Medicine, Tel-Aviv University, Israel; (4) Meir Medical Center; (5) Soroka University Medical Center; (6) Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, and Faculty of Medicine, Hebrew University, Israel; (7) Rabin Medical Center-Beilinson Campus, Israel; (8) Lin Medical Center, Clalit; (9) Kaplan Medical Center; (10) Oncology Division, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel; (11) Sheba Medical Center; (12) Ha'Emek Medical Center; (13) Rambam Medical Center; (14) Shamir (Assaf Harofeh) Medical Center; (15) BioInsight, Israel; (16) Oncotest, Rhenium, Israel.

**PO5-01-09** Exploring cellular heterogeneity of localised breast cancers. Beata Kiedik (1) Daniel Roden (1) Kate Harvey (2) Ghamdan Al-Eryani (3) Sunny Wu (4) Mun Hui (5) Sandra O'Toole (6) Elgene Lim (7) Charles Perou (8) Alex Swarbrick (9)

(1) Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia; (2) Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; (3) Broad Institute of MIT and Harvard; (4) Genentech; (5) Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; Chris O’Brien Lifehouse, Camperdown NSW, Australia; (6) Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; Department of Tissue Pathology and Diagnostic Pathology, New South Wales Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Faculty of Medicine & Health Sciences, Western Sydney University, Campbelltown, New South Wales, Australia; Sydney Medical School, Sydney University, Sydney, New South Wales, Australia; (7) Garvan Institute of Medical Research, St Vincent’s Clinical School, University of New South Wales, Australia; (8) University of North Carolina, Chapel Hill, North Carolina, United States; (9) Garvan Institute of Medical Research, Australia.
Evaluating a computer-aided platform for predicting recurrence and survival in an Oncotype Dx tested breast cancer cohort. Satabhisa Mukhopadhyay (1) Elizabeth Walsh (2) Rebecca Millican-Slater (2) Andrew Hanby (3) Joanne Stephenson (2) Tathagata Dasgupta (4) Nicolas Orsi (3)

1 4D Path Inc., Newton, Massachusetts, United States; 2 NHS; 3 St James's University Hospital, Leeds; 4 4D path Inc.


1 University of Edinburgh, Scotland, United Kingdom; 2 Biotheranostics, A Hologic Company; 3 McMaster University; 4 Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; 5 Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; 6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 7 Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom; 8 University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany; 9 National and Kapodistrian University of Athens, Medical School, Athens, Greece; 10 St. Augustinus Hospital, Antwerp, Belgium; 11 Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 12 Department of Surgery, Leiden University Medical Center; 13 University of Birmingham, Cancer Research UK Clinical Trials Unit (CRCTU), England, United Kingdom; 14 UPMC Hillman Cancer Center, University of Pittsburgh Medical Center; 15 Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, Linköping, Sweden; 16 Massachusetts General Hospital; 17 Biotheranostics, A Hologic Company, San Diego, California, United States; 18 Diagnostic Development, Ontario Institute for Cancer Research Toronto, Ontario, Canada; 19 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Factors Influencing Late Recurrence in Breast Cancer: A Comprehensive Analysis of the Impact of Hormone Therapy Regimens. Mary Rose Mendoza (1) Eun-Shin Lee (2)

1 Korea University Anam Hospital / Bicol Medical Center, Republic of Korea; 2 Korea University Anam Hospital.

Genomic risk analyses in patients with clinical low risk ER-positive HER2-negative early breast cancer developing an early metastatic event. Josephine Van Cauwenberge (1) Hava Izci (1) Hans Wildiers (2) Sileny Han (3) Christine Desmedt (4) Giuseppe Floris (2) Sara Vander Borght (5) Ann Smeets (6) Ines Nevelsteen (7) Isabelle Vanden Bempt (2) Patrick Neven (8)

1 KU Leuven; 2 University Hospitals Leuven; 3 University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium; 4 Laboratory for Translation Breast Cancer Research/KU Leuven, Leuven, Vlaams-Brabant, Belgium; 5 Department of Pathology, University Hospitals Leuven, Leuven, Belgium; 6 Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; 7 Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; 8 Universitair Ziekenhuis Leuven, Leuven, Vlaams-Brabant, Belgium.

Concerning Discrepancies in Estradiol Levels in Premenopausal Women Receiving Abemaciclib and Ovarian Function Suppression. Alaina Kessler (1) Rima Patel (1) Emily Gallagher (2)
PO5-02-02 LyKi1: a highly predictive immune-based score of pathological response to chemotherapy in luminal breast cancer.

Marc Debled (1) Hugo Deboissy (2) Coralie Cantarel (3) Chloé Delfour (2)
Léonie Alran (2) Marion Fournier (4) Nathalie Quenel-Tueux (5) Valérie Velasco (2) Foucault Chammings (6) Véronique Brouste (7) Monica Arnedos (5) Gaëtan MacGrogan (2)

(1) Institut Bergonié, France;(2) Department of Pathology, Institute Bergonié, Bordeaux, France;(3) Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Bordeaux, France;(4) institut Bergonié, France;(5) Department of Medical Oncology, Institute Bergonié, Bordeaux, France;(6) department of breast radiology, Institut Bergonié, Bordeaux;(7) Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Bordeaux, France.

PO5-02-03 Does the recommendation of adjuvant CDK4/6 inhibitors implicate more ovarian suppression in premenopausal patients? A real-world study of a public and a private Argentinean institution.


PO5-02-04 Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC).


(1) Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland;(2) Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland;(3) Department of Medical Oncology, Cork University Hospital, Cork, Ireland;(4) Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland;(5) Exact Sciences UK Ltd, London, UK;(6) Department of Medical Oncology, St James's Hospital, Dublin, Ireland;(7) Salmaniya Medical Complex, Bahrain;(8) St Vincent’s University Hospital, Dublin 4, Dublin, Ireland;(9) Department of Surgery, St Vincent’s University Hospital, Dublin, Ireland;(10) Department of Surgery, Beaumont Hospital, Dublin, Ireland;(11) Cancer Research, College of Medicine and Health, University College Cork, Ireland and Department of Medical Oncology, Cork University Hospital, Cork, Ireland;(12) Department of Medical Oncology, Cork University Hospital, Cork, Ireland;(13) Medical Oncology Department, Bon Secours Hospital, Cork, Ireland;(14) Department of Medical Oncology, ICORG/Cancer Trials Ireland, Beaumont Hospital, Royal College of Surgeons in
PO5-02-05 Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment. Donald Johann (1) Fariba Jousheghany (1) Emily Blitz (1) Bernice Nounamo (1) Sam Makhoul (2) Eric Siegel (1) Thomas Kieber-Emmons (1) Behjatolah Monzavi-Karbassi (1) (1) University of Arkansas for Medical Sciences;(2) CARTI.


PO5-02-08 Prognostic value of serum lipid levels in breast cancer patients who received neoadjuvant chemotherapy: A retrospective exploratory analysis of the prospective cohort. Xinru Chen (1) Wenjin Yin (2) Yingying Zhao (1) Jinsong Lu (2) (1) Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, China (People's Republic);(2) Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

PO5-02-09 Discordance of the PAM50 intrinsic subtypes with the immunohistochemistry-based subtypes in HER2-negative early breast cancer treated with neoadjuvant chemotherapy. Jee Hung Kim (1) Soong June Bae (2) Sung Gwe Ahn (2) Jeonghee Lim (3) Min Hwan Kim (4) Gun Min Kim (4) Joo Hyuk Sohn (5) Joon Jeong (2) (1) Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Republic of Korea;(2) Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Republic of Korea;(3) Institute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;;(4) Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine;(5) Yonsei Cancer Center, Republic of Korea.

PO5-02-10 Favorable effect of HER2-low expression on prognosis for breast cancers after neoadjuvant chemotherapy. Yingying Zhao (1) Wenjin Yin (1) Xinru Chen (2) Jingsong Lu (1) (1) Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, China (People's Republic);(2) Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, China (People's Republic).

PO5-02-11 Is There A Survival Benefit With Adjuvant Chemotherapy Use In Elderly Breast Cancer Patients? A Retrospective Study Using The National Cancer Database. Prashanth Ashok Kumar (1) Metlapalli Venkata Sranathdi (2) Dongliang Wang (2) Danning Huang (2) Abirami Sivapiragasam (3)
PO5-02-12 **Comparison of survival outcomes according to axillary ultrasonography findings and cytology results in early-stage breast cancer patients.** Suk Jun Lee (1)  
(1) Yonsei University college of Medicine.

PO5-02-13 **Distinct differences in the prognostic implication of tumor size for invasive lobular carcinoma of breast when compared to invasive ductal carcinoma.** Ik Beom Shin (1) Eunhye Kang (2) Ji-Jung Jung (3) Hawjeong Lee (1) Jin Young Byeon (1) Yunhee Choi (4) Changjin Lim (3) Jong-Ho Cheun (5) Hong-Kyu Kim (3) Han-Byoel Lee (6) Wonshik Han (7) Hyeong-Gon Moon (8)  
(1) Department of Surgery, Seoul National University Hospital;(2) Seoul National Univ. Hospital, Surgery, Republic of Korea;(3) Seoul National Univ. Hospital, Surgery, Korea;(4) Medical Research Collaborating Center, Seoul National University Hospital;(5) Seoul Metropolitan Government Seoul National University Boramae Medical Center;(6) Seoul National University Hospital;(7) Seoul National University Hospital, Republic of Korea;(8) Seoul National University, Republic of Korea.

PO5-02-14 **Clinical-pathological determinant factors to choose between four or six cycles of adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) in a retrospective real-world cohort of HER2-negative breast cancer patients.** Mila Kraychete (1) Marcelle Cesca (2) Guilherme Almeida (3) Leonardo Santana (3) Luciana Leite (3) Solange M. Sanches (4) Vladmir Cordeiro de Lima (4) Rafaela Pirolli (5) Rafael Manea (5) Felipe Kaneta (5) Jean Coutinho (5) Lucas Vian (6) Waires Zeviani (6) Marcio Reis (6) Luciana Landeiro (7) Clarissa Mathias (7) Geila Nunez (7) Tamara Santana (7) Monique Tavares (3)  
(1) AC CAMARGO CANCER CENTER, Sao Paulo, Sao Paulo, Brazil;(2) AC Camargo Cancer Center, São Paulo, Brazil,(Brazil;(3) AC CAMARGO CANCER CENTER;(4) AC CAMARGO CANCER CENTER, Sao Paulo, Brazil;(5) INSTITUTO DO CÂNCER DE LONDRINA;(6) Grupo OncoVitta Campo Grande-MS;(7) Grupo Oncoclínicas Bahia.

PO5-03-01 **Clinical outcomes of breast-conserving surgery under local anesthesia versus general anesthesia for breast malignancies.** Hawjeong Lee (1) Hyunjong Jo (2) Eunhye Kang (3) Ji-Jung Jung (4) Ik Beom Shin (1) Jin Young Byeon (1) Changjin Lim (3) Hong-Kyu Kim (4) Hyeong-Gon Moon (5) Wonshik Han (6) Han-Byoel Lee (7)  
(1) Department of Surgery, Seoul National University Hospital;(2) 1. Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea;(3) Seoul National Univ. Hospital, Surgery, Republic of Korea;(4) Seoul National Univ. Hospital, Surgery, Korea;(5) Seoul National University, Republic of Korea;(6) Seoul National University Hospital, Republic of Korea;(7) Seoul National University Hospital.

PO5-03-02 **Ductal carcinoma in situ: An excess regard of the axilla?.** Andressa Amorim (1) ANDRE MATTAR (2) Marcellus Ramos (1) REGINALDO COELHO LOPES (3) Luciana Damous (4) Luiz Henrique Gebrim (1)  
(1) Perola Byington Hospital;(2) HOSPITAL PEROLA BYINGTON, São Paulo, Sao Paulo, Brazil;(3) HOSPITAL DO SERVIDOR PUBLICO ESTADUAL;(4) Hospital do Servidor Público Estadual – Francisco Morato de Oliveira, São Paulo, Brazil.
PO5-03-03 **Nomogram for predicting brain metastasis in early-stage breast cancer patients.** Akshara Singareeka Raghavendra (1) Nuria Kotecki (2) Kristofer Jennings (3) Ottavia Amato (4) Debu Tripathy (1) Ahmad Awada (4) Nuhad Ibrahim (1)
(1) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;(2) Jules Bordet Institut;(3) University of Texas MD Anderson Cancer Center;(4) Jules Bordet Cancer Institute.

PO5-03-05 **Rethinking the value of pathologic complete response rate for the survival outcomes of early triple-negative breast cancer treated with neoadjuvant chemotherapy: a systematic review and network meta-analysis.** Xiaoying Qiao (1) Taobo Hu (2) Baosheng Liang (3) Shu Wang (2)
(1) Peking University People’s Hospital, Beijing, China (People’s Republic);(2) Breast Center - Peking University People’s Hospital;(3) School of Public Health, Peking University.

PO5-03-06 **Optimizing therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy.** Chengyue Wu (1) Ernesto Lima (1) Casey Stowers (2) Zhan Xu (3) Clinton Yam (4) Jong Bum Son (5) Jingfei Ma (5) Gaiane Rauch (6) Thomas Yankeelov (2)
(1) UT Austin, Texas, United States;(2) UT Austin;(3) MD Anderson Cancer Center, Texas, United States;(4) Breast Medical Oncology Department, The University of Texas MD Anderson Cancer Center;(5) University of Texas MD Anderson Cancer Center;(6) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

PO5-03-07 **Impact of age and stage on pathologic complete response rates in Black vs White patients with triple negative breast cancer.** Melanie Sheen (1) Caitlin Taylor (2) Rabia Cattie (2) Melyssa Bratton (2) Meredith Lakey (2) Victoria Chung (3) Erin Biggs (2)
(1) Ochsner Clinic Foundation, New Orleans, Louisiana, United States;(2) Ochsner Health;(3) Ochsner Health, New Orleans, Louisiana, United States.

PO5-03-08 **Detection and quantification of triple-negative breast cancer (TNBC) across ethnicities through analysis of cell-free DNA (cfDNA) methylation.** William Cance (1) Edison Liu (2) Margaret Antonio (1) Timothy Shaver (1) Stephannie Shih (1) Bong Chul Chu (1) Kathryn Kurtzman (1) Lisa Newman (3)
(1) GRAIL, LLC, Menlo Park, CA, USA;(2) The Jackson Laboratory for Genomic Medicine;(3) Weill Cornell Medicine, New York, New York, United States.

PO5-03-09 **Concurrent versus sequential use of adjuvant capecitabine and radiation in patients with triple-negative breast cancer with residual disease: A retrospective review.** Catherine Yu (1) Alaina Kessler (2) Theresa Shao (2) Sarah Cate (3) Paula Klein (2) Manjeet Chadha (4)
(1) Icahn School of Medicine at Mount Sinai;(2) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute;(3) Department of Surgery, Icahn School of Medicine at Mount Sinai;(4) Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai.

PO5-03-10 **The prognostic role of androgen receptor status in patients with triple negative breast cancer with an associated ductal carcinoma in situ.** Micaëlle Merckx (1)
(1) Kuleuven, Belgium.

PO5-03-11 **Ultra-low dose nivolumab added to dose-dense, cisplatin-based neoadjuvant chemotherapy in locally advanced, borderline operable triple negative breast cancer: A matched case-

PO5-03-12 Genomic differences of primary triple negative breast cancer in patients younger than 45 years vs. patients older than 45 years of age. Neelima Vidula (1) Leif Ellisen (2) Aditya Bardia (3) Christina Yau (4) (1) Harvard Medical School, Massachusetts General, Boston, Massachusetts, United States; (2) Massachusetts General Hospital, Boston, Massachusetts, United States; (3) Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States; (4) University of California, San Francisco and Buck Institute for Research on Aging, Novato, California.

PO5-04-01 Inetetamab combined with sirolimus and chemotherapy in HER2 positive metastatic breast cancer patients with abnormal activation of PI3k/Akt/mTOR pathway after trastuzumab treatment. Qiao li (1) Dan Lv (1) Xiaoying Sun (2) Mengyuan Wang (3) Li Cai (4) Feng Liu (5) chenghui li (6) Jiuda Zhao (7) jing sun (8) Yehui Shi (9) Fei Ma (10) (1) National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China (People's Republic); (2) Cancer Hospital of Huanxing Chaoyang District, Beijing 100122, China.; (3) Department of Breast surgery, Chongqing University Three Gorges Hospital; (4) Harbin Medical University Cancer Hospital, Harbin, China., China (People's Republic); (5) Fuyang Cancer Hospital, Anhui, China., China (People's Republic); (6) Anqing Cancer Hospital, Anhui, China., China (People's Republic); (7) Qinghai University Affiliated Hospital, Qinghai, China., China (People's Republic); (8) Anyang Cancer Hospital, Henan, China.; (9) Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., China (People's Republic); (10) Cancer Hospital, Chinese Academy of Medical Sciences, China.

PO5-04-02 Combination of trastuzumab competing and non-competing fully human internalizing anti-Her2 monoclonal antibodies drug conjugates increases their inhibitory effect on the growth of HER2 positive metastatic breast cancer cells. Ginette Serrero (1) Binbin Yue (2) Jianping Dong (3) Jun Hayashi (4) (1) A&G Pharmaceutical Inc, Columbia, Maryland, United States; (2) A&G Pharmaceutical, Columbia, Maryland, United States; (3) A&G Pharmaceutical Inc., Columbia, Maryland, United States; (4) Precision Antibody, Columbia, Maryland, United States.

PO5-04-03 Withdrawn

PO5-04-04 Development of a method to detect very low levels of HER2 expression in Circulating Tumor Cells (CTCs) by liquid biopsy in patients with metastatic breast cancer. Giuseppe Di Caro (1) David Bourdon (2) Andrew Kunihiro (1) Alessandra Cunsolo (1) Ernest Lam (1) Megan Slade (3) Martin Blankfard (1) Lee Schwartzberg (1) (1) Epic Sciences; (2) Epic Sciences, San Diego, California, United States; (3) Epic Sciences, California, United States.
PO5-04-05 Clinical validation of the concordance performance of ERBB2 status by single-cells genomics ERBB2 (HER2) amplification Assay in Circulating Tumor Cells (CTCs) from patients with matched HER2 status from metastatic tissue biopsies. Giuseppe Di Caro (1) Ernest Lam (1) Megan Slade (2) Shuguang Huang (3) Rick Wenstrup (1) Lee Schwartzberg (1) (1) Epic Sciences; (2) Epic Sciences, California, United States; (3) Stat4Ward.

PO5-04-06 Enhancing Antitumor Activity of Her2 CAR T cells through TR2BB Co-Expression and Cytokine Signal 3 Incorporation. Diego Chamorro (1) Lauren Somes (1) Emily Madaras (2) Saisha Nalawade (3) Paul Shafer (3) Andres Mosquera (3) Mary Kathryn McKenna (3) Valentina Hoyos (3) (1) Baylor College of Medicine, Houston, Texas, United States; (2) Rice University; (3) Baylor College of Medicine.


PO5-04-10 Clinical and prognostic value of MLN51 (Metastatic lymph node gene 51)/CASC3 (Cancer susceptibility candidate gene 3) in clinical breast cancer, connection with nodal and hormonal receptor status. BINBIN CONG (1) Tracey Martin (2) XIAOSHAN CAO (3) ROBERT E MANSEL (4) Eleri Davies (5) Wen Jiang (2) (1) 1. Cardiff University School of Medicine; 2. Shandong Cancer Hospital and Institute; (2) Cardiff University; (3) Cardiff University School of Medicine; 2. Tianjin Medical University; 3. Shandong Cancer Hospital and Institute; (4) University Llandough Hospital; (5) 3Wales Breast Centre, University Llandough Hospital, Cardiff CF64 2XX, UK.

PO5-04-11 Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor positive advanced breast cancer: a systematic review and meta-analysis. Neha Pathak (1) Sudhir Kumar (2) Diego Malon Gimenez (3) Massimo Di Iorio (4) Consolacion Molto Valiente (3) Danielle Cuthbert (3) Meredith Li (3) Atul Batra (5) Michelle Nadler (6) Eitan Amir (6) Abhe-nil Mittal (7) (1) Princess Margaret Cancer Centre, Division of Medical Oncology, Toronto, ON, Canada. University of Toronto, Department of Medicine, Toronto, ON, Canada. (2) Sunnybrook Health Sciences Centre, Ontario, Canada. (3) Princess Margaret Cancer Centre, Division of Medical Oncology, Toronto, ON, Canada. University of Toronto, Department of Medicine, Toronto, ON, Canada. (4) Princess Margaret Cancer Centre, University of Toronto; (5) India Institute of Medical Sciences, New Delhi, India; (6) Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada; (7) Princess Margaret Cancer Centre, Division of Medical Oncology, University of Toronto, Department of Medicine, Toronto, ON, Canada.

PO5-04-12 Comparison of chemotherapy efficacy in metastatic lobular vs. ductal breast cancer. Brendan Kirwin (1) Arlene Chan (2)

(1) Genekor Medical SA, Greece; (2) GeneKor Medical SA, Greece; (3) GeneKor Medical SA; (4) Interbalkan European Medical Center, Greece; (5) Metropolitan Hospital, Greece; (6) National Kapodistrian University of Athens, Greece; (7) General Hospital of Athens Alexandra, Athens, Greece; (8) University Hospital of Ioannina, Greece; (9) Hygeia Hospital; (10) Agios Savvas Anticancer Hospital, Greece; (11) Euromedica, General Clinic of Thessaloniki, Greece; (12) Laiko University Hospital, Greece; (13) Mitera Hospital, Greece.

**PO5-04-14 Quality of Life (QoL) among metastatic hormone receptor positive, HER2 negative breast cancer patients during first line systemic treatment.** Débora Gagliato (1) Julio Antonio Araujo (2) Bianca Milena Verboski (3) Guilherme William Marcelino (4) Fabiana Nogueira Momberg (3) Gilmara Silveira da Silva (5) Rozana Mesquita Ciconelli (6) Antônio Buzaid (7)

(1) Hospital Beneficiência Portuguesa, São Paulo, Brazil, Brazil; (2) BP; (3) BP de Sao Paulo; (4) BP de Sao Paulo; (5) Bp de Sao Paulo; (6) Bp de Sao Paulo; (7) Centro Oncológico Antonio Ernirio de Morais - Beneficiência Portuguesa de Sao Paulo.

**PO5-05-01 ASSESSING THE CLINICAL AND SURVIVAL RESULTS OF PATIENTS WITH HR-POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER TREATED WITH CDK 4/6 INHIBITORS IN A SPANISH COHORT.** Alicia Cano-Jimenez (1) Rocio Urbano-Cubero (1) Ruben Garcia-Munioz (1) Ana Maria Jaen-Morago (1) Maria Lomas-Garrido (1) Pedro Sánchez-Rovira (2)

(1) Hospital Universitario de Jaen; (2) Hospital Universitario de Jaén, Jaén, Spain, Andalucia, Spain.

**PO5-05-02 Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer.** Hannah Majeski (1) Akinori Okano (1) Kirti Chahal (1) Angela Pasis (1) Casey Carlson (1) Arvind Sharya (1) Qiao Liu (1) Shenlin Huang (1) Aparajita Hoskote Chourasia (1) Leah Fung (1)

(1) Biotheryx.


(1) Memorial Sloan Kettering Cancer Center, New York, New York, United States; (2) START Midwest; (3) Valkyrie Clinical Trials; (4) Stanford, Stanford, California, United States; (5) eFFECTOR Therapeutics; (6) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
PO5-05-04 Advancing Treatment and Management of Patients with HR+/HER2- Breast Cancer: Findings from a Quality Improvement Initiative. Jane Meisel (1) Chelsie Anderson (2) Ilona Dewald (2) Jeffrey Carter (2) Cherilyn Heggen (2) Kelly McKinnon (3)
(1) Winship Cancer Institute, Atlanta, Georgia, United States;(2) PRIME Education;(3) PRIME Education, Georgia, United States.

PO5-05-05 Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer. Mahta Mardani (1) Suleyman Noordeen (1) Katherine Clifton (2) Cynthia Ma (3) Jingqin Luo (2) Jing Xi (1) Nusayba Bagegni (2) Foluso Adeyemiwa (2) Rama Suresh (2) Ashley Frith (2) Andrew Davis (2) Ron Bose (4) Lindsay Peterson (4) Shana Thomas (5) Yu Tao (6) Takayuki Kobayashi (1) Jingyu Xiang (1) Yalin Xu (7) Ximing Su (8) Katherine Weilbaecher (9)
(1) Washington University in St. Louis School of Medicine;(2) Washington University in St Louis School of Medicine;(3) Washington University in St. Louis, St. Louis, Missouri, United States;(4) Washington University in St Louis School of Medicine, St. Louis, Missouri, United States;(5) Washington University in St Louis School of Medicine, Fenton, Missouri, United States;(6) Washington University in St. Louis MO;(7) Washington University in St.Louis school of medicine;(8) Washington University in St.Louis, school of Medicine;(9) Washington University School of Medicine.

PO5-05-07 Efficacy and safety of first line CDK4/6i plus endocrine therapy for patients with HR+/HER2-metastatic breast cancer: initial real-world experience at Ho Chi Minh city oncology hospital, Viet Nam. Hoang-Quy Nguyen (1) Hong-Duc Phan-Thi (2) Thi-Hong-Van Le (2)
(1) HCMC, Oncology Hospital;(2) HCMC Oncology Hospital.

PO5-05-08 LOSS OF SINGLEMINDED 2S RESULTS IN A PI3K SUBUNIT SWITCH WHICH DRIVES THERAPEUTIC RESISTANCE IN ESTROGEN RECEPTOR POSITIVE BREAST CANCER. Garhett Wyatt (1) Rachel Steinmetz (2) Traci Lyons (2) Weston Porter (1)
(1) Texas A&M University;(2) CU Anschutz Medical Campus.

(1) University of Houston, Houston, Texas, United States;(2) University of Houston;(3) Georgetown University;(4) AbbVie;(5) UH Seq-N-Edit Core (SNEC), University of Houston;(6) Baylor College of Medicine;(7) University of Houston-Downtown.


(1) UPMC Department of Surgery, Breast Health Working Group International;(2) Breast Health Working Group International;(3) Bahcesehir University, Department of Surgery, Turkey;(4) KING FAHAD SPECIALIST HOSPITAL, DEPARTMENT OF SURGERY;(5) Uludag University, Faculty of Medicine, Department of Surgery, Turkey;(6) Ege University, Medical Faculty, Department of General Surgery, Turkey;(7) MD ANDERSON CANCER CENTER;(8) MD Anderson Cancer Center;(9) Ankara Memorial Hospital, Medical Oncology Center, Ankara, Turkey, Ankara, Turkey;(10) Istanbul University Institute of Oncology, Department of Surgical Oncology, Turkey;(11) Acibadem University, Faculty of Medicine, Department of Surgery, Turkey;(12) Mersin University, Faculty of Medicine, Department of Surgery, Turkey;(13) MEDIPOL UNIVERSITY, DEPARTMENT OF MEDICAL ONCOLOGY, Turkey;(14) Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital;(15) Ankara City Hospital, Medical Oncology Clinic, Ankara, Turkey, Ankara, Turkey;(16) SELCUK UNIVERSITY MEDICAL SCHOOL, GENERAL SURGERY DEPARTMENT;(17) University of Health Sciences, Gulhane Hospital, Department of Surgery, Turkey;(18) Istanbul University, Istanbul Faculty of Medicine, Department of Surgery, Turkey;(19) Ege University, Faculty of Medicine, Department of Surgery, Turkey;(20) Kocaeli University, Faculty of Medicine, Department of Surgery, Turkey;(21) University of Health Sciences Gulhane Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey, Ankara, Turkey, Ankara, Turkey;(22) PRIVATE PRACTICE;(23) KOCAEII UNIVERSITY MEDICAL SCHOOL, GENERAL SURGERY DEPARTMENT;(24) Elazig Medical Park Hospital, Medical Oncology Department;(25) Acibadem MAA University, Research Institute of Senology, Head;(26) UNIVERSITY OF HEALTH SCIENCES, DR ABDURRAHMAN YURTASLAN ANKARA ONCOLOGY TRAINING AND RESEARCH HOSPITAL, GENERAL SURGERY DEPARTMENT;(27) Ankara Oncology Hospital, Department of Surgery, Turkey;(28) Istanbul Medeniyet University;(29) Bursa Yuksek Ihtisas Training and Research Hospital, General Surgery, Bursa, Turkey;(30) ISTANBUL FLORENCE NIGHTINGALE HOSPITAL, DIRECTOR OF BREAST CENTER;(31) MD Anderson Cancer Center, Houston, Texas, United States.

PO5-05-13 Clinical utility of whole body low dose computed tomography for detecting bone metastasis in breast cancer patients: A cross sectional study. Lipton Mitra (1) Suhani Suhani (1) Ankur Goyal (2) Rakesh Kumar (2) Mohit Joshi (2) Hemanga Bhattacharjee (2) Haresh KP (2) Raju Sharma (2) Rajinder parshad (2)
(1) All India Institute of Medical Sciences, New Delhi, Delhi, India;(2) All India Institute of Medical Sciences, Delhi, India.

PO5-05-14 Survival in Young Women with De Novo or Recurrent Metastatic Breast Cancer. Leticia Varella (1) Yue Zheng (2) Shoshana Rosenberg (3) Gregory Kirkner (4) Craig Snow (2) Kathryn Ruddy
PO5-06-01 Loss of hormone receptor expression in breast cancer is associated with increased brain tropism and accelerated progression of leptomeningeal disease. Sophia Pribus (1) Maxine C. Umeh-Garcia (1) Bo Gu (1) Bryanna Godfrey (1) Summer Han (1) Sophia Chernikova (1) Melanie Hayden Gephart (1)
(1) Stanford University.

(1) UT MD Anderson Cancer Center, Houston, Texas, United States;(2) MD Anderson Cancer Center;(3) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;(4) UT MD Anderson Cancer Center;(5) The University of Texas MD Anderson Cancer Center, Texas, United States;(6) UT MD Anderson Cancer Center, Houston, TX, Texas, United States;(7) The University of Texas MD Anderson Cancer Center; (10) University of Hawai'i Cancer Center, Honolulu, HI, USA;(11) Baylor College of Medicine, Houston, Texas, United States;(12) Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Bellaire, Texas, United States.

PO5-06-03 Impact of curative-intent treatment on survival for metastatic breast cancer limited to distant lymph nodes. Yang Xu (1)
(1) Tom Baker Cancer Center.

PO5-06-04 EMSY amplification co-occurs with FGF/FGFR axis amplification in Metastatic Breast Cancer. Deepika Prasad (1) Edik Blais (2) Rick Dunetz (3) Emanuel Petricoin (4) Mariaelena Pierobon (1)
(1) George Mason University;(2) Perthera inc;(3) Side Out Foundation;(4) George Mason University, Manassas, Virginia, United States.

PO5-06-05 DISCORDANCE BETWEEN HORMONE RECEPTORS AND HER2 STATUS IN BREAST CANCER PATIENTS RELAPSE. Katia Roque (1) Iris Otoya (2) NATALIA VALDIVIESO (3) Zaida Morante (4) Hugo Fuentes (4) Silvia Neciosup (4) Henry Gómez (5) Jorge Cotito (4) Gonzalo Ziegler (4) Estefania Peña (4) Tatiana Vidaurre (4) Ramon Andrade de Mello (6) Carlos Castañeda (4)
PO5-06-06 **Tumor/stromal expression of CD3/CD8/PD-1/PD-L1 and overall survival (OS) in patients (pts) with metastatic (met) HER2+ breast cancer (BC).**

Denis Collins (1)  Janet McCormack (2)  Laura Ivers (3)  Jose Javier Berenguer-Pina (4)  Jo Ballot (5)  Cecily Quinn (6)  Darko Skrobo (7)  Alex Eustace (8)  Naomi Walsh (3)  Aurelie Fabre (9)  John Crown (10)

(1) Cancer Biotherapeutics, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland; (2) UCD Conway Institute, Dublin, Dublin, Ireland; (3) Dublin City University, Dublin 9, Dublin, Ireland; (4) Dept of Medical Oncology, Saint Vincent's University Hospital, Dublin, Ireland; (5) Department of Medical Oncology, St Vincent’s University Hospital, Dublin, Ireland; (6) St. Vincent's University Hospital, Dublin, Ireland; (7) Galway University hospital; (8) Dublin City University, Ireland; (9) Saint Vincent's University Hospital, Dublin, Ireland; (10) St Vincent’s University Hospital, Dublin 4, Dublin, Ireland.

PO5-06-07 **Unravelling the role of PKC-eta in modulating the Hippo Pathway: a novel therapeutic strategy for triple-negative breast cancer metastasis.**

Liju Vijaya Steltar Belsamma (1)  Amitha Muraleedharan (2)  Divya Ram Jayaram (1)  Kamran Waidha (1)  Sankar Jagadeeshan (1)  Rose Sinay (2)  Ekaterina Eremenko (2)  Omer Berner (1)  Moshe Elkabets (1)  Etta Livneh (2)

(1) Ben-Gurion University of the Negev, Beersheva, Israel; (2) Ben-Gurion University of the Negev, Beersheva, Israel.

PO5-06-08 **Real-world analysis of efficacy, adverse events and predictive biomarkers for advanced triple negative breast cancer (TNBC) treated with immune check point Inhibitors (ICI): A single center experience.**

Archit Patel (1)  Arya Mariam Roy (2)  Malak Alharbi (1)  Kristopher Attwood (1)  Chi-Chen Hong (1)  Song Yao (3)  Thaer Khoury (4)  Amy Early (1)  Tracey O'Connor (1)  Ellis Levine (1)  Shipra Gandhi (1)

(1) Roswell Park Comprehensive Cancer Center; (2) Roswell Park Comprehensive Cancer Center, Amherst, New York, United States; (3) Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY; (4) Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO5-06-09 **Metastatic triple negative breast cancer has distinct tumor immune landscape.**

Robert Seager (1)  Heidi Ko (2)  Sarabjot Pabla (1)  Maria-Fernanda Senosain (3)  Erik Van Roey (3)  Shuang Gao (4)  Kyle Strickland (2)  Rebecca Previs (2)  Mary Nesline (2)  Stephanie Hastings (2)  Shengle Zhang (2)  Jeffrey Conroy (5)  Taylor Jensen (2)  Marcia Eisenberg (6)  Brian Caveney (6)  Eric Severson (2)  Shakti Ramkissoon (2)  Shipra Gandhi (7)

(1) Omniseq; (2) Labcorp Oncology; (3) Omniseq (Labcorp Oncology); (4) Labcorp, Buffalo, New York, United States; (5) OmniSeq, Inc., Buffalo, New York, United States; (6) Labcorp; (7) Roswell Park Comprehensive Cancer Center.
(1) Association of Community Cancer Centers (ACCC); (2) University of California, San Francisco; (3) University of Rochester Medical Center, Rochester, New York, United States; (4) Tigerlily Foundation.; (5) Middlesex Health Cancer Center; (6) University of Houston-Downtown; (7) Mayo Clinic Alix School of Medicine; (8) Tigerlily Foundation; (9) Rhizome, LLC; (10) Association of Community Cancer Centers.

PO5-06-11 RPL27A promotes the growth and metastasis of triple negative breast cancer by regulating Ribosome biogenesis. Weipeng Zhao (1) jingyi Zhang (2) ye Zhu (2) xin Yang (2) Xichuan Li (3)
(1) Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy.; (2) National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy.; (3) Tianjin Normal University.

PO5-06-12 Genetic screen identifies epigenetic drivers of breast cancer brain metastasis. Jocelyn Chen (1) Wesley Cai (1) Peng Xu (1) Don Nguyen (1) Qin Yan (1)
(1) Yale University.

PO5-06-13 Impact of Therapy on Sites of Metastases in Triple Negative Breast Cancer. Hannah Chang (1) Pallavi Dev (2) Luise Froessl (2) Shao-Po Huang (2) Christine Hodgdon (3) Julia Maues (4) Isaac Chan (5)
(1) University of Texas at Southwestern, Dallas, Texas, United States; (2) University of Texas at Southwestern; (3) Grasp Cancer; (4) GRASP, Washington, District of Columbia, United States; (5) University of Texas Southwestern Medical Center.

PO5-06-14 Genomic Landscape and Clinical Outcomes of Triple-Negative Invasive Lobular Carcinoma. Hemali Batra-Sharma (1) Smruthy Sivakumar (2) Prashanth Ashok Kumar (3) Ethan Sokol (4) Rebecca Shatsky (5) Jeffrey Ross (2)
(1) University of California San Diego Moores Cancer Center; (2) Foundation Medicine Inc.; (3) SUNY Upstate Medical University, Syracuse, New York, United States; (4) Foundation Medicine Inc.; (5) University of California at San Diego.

PO5-07-01 A novel clinical risk score that can accurately predict the survival of young breast cancer patients: A UAE-based cohort study. Aydah Al-Awadhi (1) Mohammed Hourani (2) Mawada Hussein (2) Fatima Alkindi (3) Lina Wahba (4) Abla AlAgha (5) Alaa Shoqier (6) Mouza AlShebli (7) Atlal Abusanad (8) Amar Ahmad (9)
(1) department of Medical Oncology, Tawam hospital - SEHA; (2) Department of Medical Oncology - Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; (3) Department of Internal Medicine - Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; (4) Department of Clinical Pharmacy - Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; (5) Department of Internal Medicine - Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; (6) Department of Academic affairs - Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE, Abu Dhabi, United Arab Emirates; (7) Department of Internal Medicine, University of Toronto, Canada; (8) Faculty of medicine, King Abdulaziz university; (9) New York University Abu Dhabi, Cancer Research UK (CRUK).
PO5-07-02 **AI-assisted interpretation of PD-L1 CPS improves the precision medicine in Triple-negative breast cancer.** Jinze Li (1) Xinran Wang (1) Yueping Liu (1)
(1) Department of Pathology, The Fourth Hospital of Hebei Medical University.

PO5-07-03 **Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy.** Casey Stowers (1) Chengyue Wu (2) Sidharth Kumar (3) Zhan Xu (4) Clinton Yam (5) Jong Bum Son (6) Jingfei Ma (6) Jonathan Tamir (3) Gaiane Rauch (7) Thomas Yankeelov (8)
(1) University of Texas at Austin, Austin, Texas, United States;(2) UT Austin, Texas, United States;(3) University of Texas at Austin;(4) MD Anderson Cancer Center, Texas, United States;(5) Breast Medical Oncology Department, The University of Texas MD Anderson Cancer Center;(6) University of Texas MD Anderson Cancer Center;(7) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;(8) UT Austin.

(1) Ribeirão Preto Medical School, University of São Paulo, Brazil;(2) Departamento de Ciência da Computação, Instituto de Matemática e Estatística, University of São Paulo, Brazil;(3) Barretos Cancer Hospital, Barretos, Brazil;(4) Barretos Cancer Hospital, Barretos, Brazil;(5) Women's Health Reference Center of Ribeirão Preto (MATER), Ribeirão Preto Medical School, University of São Paulo, Brazil;(6) Barretos Cancer Hospital, Campo Grande, Brazil, Brazil;(7) Faculdade Estadual de Tecnologia de Ribeirão Preto - Centro Paula Souza, Brazil, Brazil;(8) University of Sao Paulo.

PO5-07-05 **Deep learning can diagnose axillary lymph node metastases on optical virtual histologic images in breast cancer patients during surgery.** Shuwei Zhang (1) Houpu Yang (1) Jin Zhao (1) Shu Wang (1)
(1) Peking University People’s Hospital Breast Center.

PO5-07-06 **Impact of patient-specific factors on quantitative breast parenchymal texture features.** Sarah Nyante (1) Yukie Kajita (1) Walter Mankowski (2) Ley Killeya (1) Despina Kontos (3) Xianming Tan (4) Eric Cohen (5) Cherie Kuzmiak (6)
(1) University of North Carolina at Chapel Hill;(2) University of Pennsylvania, Philadelphia, Pennsylvania, United States;(3) Department of Radiology, University of Pennsylvania;(4) UNC Lineberger Comprehensive Cancer Center;(5) University of Pennsylvania;(6) University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States.

PO5-07-07 **The biological basis of breast MRI background parenchymal enhancement in women with high breast cancer risk.** Pegah Khoshpouri (1) Anum Kazerouni (2) Sana Parsian (2) Daniel Hippe (2) Olivia Walsh (2) Lisa Koch (2) Savannah Partridge (2) Habib Rahbar (2)
(1) University of Washington, Seattle, Washington, United States;(2) University of Washington.

PO5-07-08 **A Serum Biomarker for the Early Detection of Breast cancer.** christine chavany (1) Jeffrey Dea (1) Monica Guevara (2) Rafael Hernandez-Gonzalez (2) Patrizia Ferroni (3) Fiorella Guadagni (3) Rosaura Valle (1) Moncef Jendoubi (1)
PO5-07-09 ACCURACY OF STEREOTACTIC VACCUM-ASSISTED BREAST BIOPSY FOR INVESTIGATING SUSPICIOUS CALCIFICATIONS IN 2,021 PATIENTS A PUBLIC HOSPITAL IN BRAZIL. Andressa Amorim (1) ANDRE MATTAR (2) MARCELO ANTONINI (3) REGINALDO COELHO LOPES (4) Luciana Damous (5) Luiz Henrique Gebrim (1) Marina Diogenes (6) Marcellus Ramos (1) (1) Perola Byington Hospital;(2) HOSPITAL PEROLA BYINGTON, São Paulo, Sao Paulo, Brazil;(3) HOSPITAL DO SERVIDOR PUBLICO ESTADUAL, Sao Paulo, Sao Paulo, Brazil;(4) HOSPITAL DO SERVIDOR PUBLICO ESTADUAL; (5) Hospital do Servidor Público Estadual – Francisco Morato de Oliveira, São Paulo, Brazil.;(6) HOSPITAL PEROLA BYINGTON, SÃO PAULO, Sao Paulo, Brazil.

PO5-07-10 CONTRAST MAMMOGRAPHY FOR PREOPERATIVE STAGING OF PATIENTS WITH EARLY BREAST CANCER: PRELIMINARY RESULTS. Andressa Amorim (1) ANDRE MATTAR (2) Almir Bitencourt (3) Paula Moraes (3) Flora Finguerman (3) (1) Perola Byington Hospital;(2) HOSPITAL PEROLA BYINGTON, São Paulo, Sao Paulo, Brazil;(3) DASA.

PO5-07-11 Use of 64Cu-DOTA trastuzumab-PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress. Joanne Mortimer (1) Kofi Poku (2) Jessica liu (2) Russell Rockne (3) chen Bihong (2) Ryan Woodall (2) Vikram Adhikarla (3) (1) City of Hope, Duarte, California, United States;(2) City of Hope;(3) Beckman Research Institute.

PO5-07-12 Feasibility of organized population-based mass-level mammography screening (0.2 million women) –Report from LMIC-Uzbekistan. Mirzagaleb Tillyashaykhov (1) Aysulu Seytmuratova (1) Alexander Ososkov (1) Saide Djanklich (1) Yakhyo Ziyaev (1) Dinesh Pendharlkar (2) (1) Republian Specialised scientific practical medical center of Oncology and Radiology of Uzbekistan;(2) Sarvodaya cancer institute, Faridabad, Haryana, India.

PO5-08-01 Investigating the Link between APC I1307K Mutation and Breast Cancer in Arab Population. Baha' sharaf (1) Hira Bani Hani (2) Anas Zayed (3) Maha Barbar (4) Ahmad Hushki (5) Rashid Abdel-Razeq (6) Mohammad Titi (5) Reem Al-Halalsheh (4) Suleiman Mahafdah (7) Hikmat Abdel-Razeq (6) (1) King Hussien Cancer Center, Jordan;(2) King Hussien Cancer Center;(3) Khcc, Jordan;(4) king hussien cancer center;(5) KING HUSSIEN CANCER CENTER;(6) King Hussein Cancer Center, Jordan;(7) King Hussein cancer center.

PO5-08-03 *Breastfeeding and Breast Cancer Screening Among Carriers of Pathogenic Variants in BRCA 1 and BRCA 2 and Other High Penetrance Genes: Knowledge and Perspectives*. Laura Pacheco-Spann (1) Mark Sherman (1) Susan Friedman (2) Diane Rose (2) Miriam Levi (1) Alex hochwald (1) Jennifer Ridgeway (1) Sophia Blumenfeld (1) (1) Mayo Clinic; (2) Facing Our Risk of Cancer Empowered.

PO5-08-04 *Characteristics of breast cancer in carriers of pathogenic variant in ATM in a large academic health center*. Ujjwal Karki (1) Tara Rangarajan (2) Dana Zakalik (2) (1) Corewell Health William Beaumont University Hospital; (2) Corewell Health - Nancy & James Grosfeld Cancer Genetics Center.

PO5-08-05 *Breast Cancer in PMS2 related Lynch Syndrome: evidence of a possible association?*. Ujjwal Karki (1) Tara Rangarajan (2) Dana Zakalik (2) (1) Corewell Health William Beaumont University Hospital; (2) Corewell Health - Nancy & James Grosfeld Cancer Genetics Center.

PO5-08-06 *Metabolic shift to serine pathway induced by lipids confers oncogenic properties in non-transformed breast cells*. Mariana Bustamante Eduardo (1) Gannon Cottone (2) Shiyu Liu (3) Maria Paula Zappia (4) Elizaveta V. Benevolenskaya (4) Abul Bashar Mir Md. Khademul Islam (4) Maxim V. Frolov (4) Seema Khan (5) Susan Clare (6) (1) Surgery, Breast Surgery Division; Feinberg School of Medicine; (2) Northwestern University; (3) Duke University; (4) University of Illinois at Chicago; (5) Northwestern University, Chicago, Illinois, United States; (6) Surgery, Breast Surgery Division, Feinberg School of Medicine.

PO5-08-07 *Ki-67 Expression in Breast Cancer associated with ATM, BRCA1, BRCA2, CHEK2 and PALB2 Pathogenic Variants*. Robert Scheel (1) Grace Choong (2) Tara Rao (1) Nicholas Boddicker (2) Chunling Hu (2) Jie Na (2) Vinod Kaggal (1) Sean Murphy (1) Karthik Giridhar (3) Saba Yasir (1) Matthew Goetz (3) Fergus Couch (3) Siddhartha Yadav (3) (1) Mayo Clinic - Rochester; (2) Mayo Clinic; (3) Mayo Clinic, Rochester, Minnesota, United States.

PO5-08-08 *Tumor Registry Guided Genetic Testing: Opportunities Unlocked*. Kevin Hughes (1) Antoine Finanos (1) Kiersten Meeder (1) (1) Medical University of South Carolina.

PO5-08-09 *Li Fraumeni Syndrome in Breast Cancer Patients of Ceará/Brazil: correlations of genotype - fenotype*. Rosane Sant’Ana (1) Isabelle Joyce Fernandes (2) Maria Claudia Luciano (2) Maria Julia Bezerra (2) Flavio Bitencourt (3) Clarissa Albuquerque (2) Paulo Goberlanio Silva (2) José Fernando De Moura (2) Francisca Fernanda Oliveira (2) (1) Instituto do Câncer do Ceará, FORTALEZA, Ceará, Brazil; (2) Instituto do Câncer do Ceará, Fortaleza, Ceará, Brazil; (3) Instituto do CÂncer do Ceará, Fortaleza, Ceará, Brazil.
PO5-08-10 **Breast cancer risk prediction performance of polygenic risk score in Taiwanese female with dense breast: A nested case-control study.** Chih Yean Lum (1) Chih Chiang Hung (2) Chi-Cheng Huang (3) Tzu-Hung Hsiao (2) Sin-Hua Moi (4)
(1) Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China); (2) Taichung Veterans General Hospital; (3) Taipei Veterans General Hospital; (4) Kaohsiung Medical University.

(1) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, New York, United States; (2) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; (3) New York Presbyterian/Weill Cornell Medical Center, New York, United States; (4) Weill Cornell Medicine; (5) Dana-Farber Cancer Institute, Massachusetts, United States; (6) Weill Cornell Medical College, New York, United States; (7) New York Presbyterian/Weill Cornell Medical Center/Columbia University, New York, NY; (8) Weill Cornell Medicine, New York, New York, United States.

PO5-08-12 **Ethnic Admixture Affects Breast Cancer Incidence in Native Hawaiians: The Multiethnic Cohort.** Dustin Valdez (1) Arianna Bunnell (2) David Bogumil (3) Gertraud Maskarinec (1) John Shepherd (1)
(1) University of Hawaii Cancer Center; (2) University of Hawaii at Manoa; (3) University of Southern California.

PO5-09-01 **Relative low body mass index (BMI) and fat quantity predicts prognosis better than absolute BMI in hormone receptor-positive, HER2-negative breast cancer.** Eunhye Kang (1) Ji-Jung Jung (2) Ik Beom Shin (3) Hawjeong Lee (3) Jin Young Byeon (3) Changjin Lim (2) Hong-Kyu Kim (2) Hyeong-Gon Moon (4) Wonshik Han (5) Jong-Ho Cheun (6) Soon Ho Yoon (7) Han-Byoel Lee (8)
(1) Seoul National Univ. Hospital, Surgery, Republic of Korea; (2) Seoul National Univ. Hospital, Surgery, Korea; (3) Department of Surgery, Seoul National University Hospital; (4) Seoul National University, Republic of Korea; (5) Seoul National University Hospital, Republic of Korea; (6) Seoul Metropolitan Government Seoul National University Boramae Medical Center; (7) Department of Radiology, Seoul National University College of medicine; (8) Seoul National University Hospital.

PO5-09-02 **Breast Tissue Proteomic Profile of Breast Cancer in Premenopausal Women and Association with Mammographic Breast Density.** Shaili Tapiavala (1) Minsoo Son (1) Graham Colditz (2) Ah Young Goo (1) Adetunji Toriola (3)
(1) Washington University School of Medicine, St. Louis; (2) Washington University School of Medicine, Saint Louis, Missouri, United States; (3) Washington University School of Medicine, St. Louis, Missouri, United States.

PO5-09-03 **Multi-tissue transcriptome-wide association studies identified genes for intrinsic subtypes of breast cancer.** James Li (1) Julian McClellan (1) Haoyu Zhang (2) Guimin Gao (3) Dezheng Huo (4)
(1) Department of Public Health Sciences, University of Chicago; (2) National Cancer Institute, Division of Cancer Epidemiology and Genetics; (3) University of Chicago; (4) Department of Public Health Sciences, University of Chicago and Center for Clinical Cancer Genetics & Global Health, Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, United States.
PO5-09-04 Oncotype DX Breast Recurrence Score® analysis in early-stage breast cancer associated with CHEK2, ATM and PALB2 germline pathogenic variants. Fatma Akkoc Mustafayev (1) Angelica Gutierrez Barrera (2) Diane Liu (3) Banu Arun (4) (1) University of Texas MD Anderson Cancer Center;(2) University of MD Anderson Cancer Center;(3) UT MD Anderson Cancer Center;(4) UT MD Anderson Cancer Center, Houston, Texas, United States.

PO5-09-05 Characteristics of newly diagnosed breast cancer patients at a large safety-net system: Implications for health equity and care delivery. Sarah Kashanian (1) Shifa Kanjwal (2) L. Steven Brown (3) Andrea Semlow (3) Mary Hodges (3) Robyn Cobb (3) Brad Walsh (3) Umber Dickerson (3) Navid Sadeghi (1) (1) University of Texas Southwestern Medical Center, Dallas, Texas, United States;(2) University of Texas Southwestern Medical Center;(3) Parkland Health.

PO5-09-06 Outcomes of breast cancer in a minority-enriched population treated at a large safety-net system: Is site of care a predictor of poor outcomes?. Sarah Kashanian (1) Shifa Kanjwal (2) L. Steven Brown (3) Andrea Semlow (3) Mary Hodges (3) Robyn Cobb (3) Brad Walsh (3) Umber Dickerson (3) Navid Sadeghi (1) (1) University of Texas Southwestern Medical Center, Dallas, Texas, United States;(2) University of Texas Southwestern Medical Center;(3) Parkland Health.

PO5-09-07 Withdrawn

PO5-09-08 Cancer Health Disparities among non-Hispanic African women: A systematic review of the disparities, reasons and probable intervention. Tasnuva Khan efa (1) (1) University of Texas Health Science at Houston, Arlington, Texas, United States.


PO5-09-10 Inflammatory Breast Cancer Patient Profile in a Population of Puerto Rican Women. LUZ ARROYO-CRUZ (1) Michelle Martinez-Montemayor (1) (1) Universidad Central del Caribe, Bayamón, Not Applicable, Puerto Rico.

PO5-09-11 Abrupt involution of mouse mammary gland leads to inflammatory systemic changes along with mammary specific metabolic shifts that may enhance risk of breast cancer. Kate Ormiston (1) Kirti Kaul (2) Neelam Shinde (2) Djawed Bennouna (3) Rachel Kopec (3) Ramesh Ganju (2) Sarmila Majumder (3) Bhuvaneswari Ramaswamy (4) (1) The Ohio State University Medical Center, Westerville, Ohio, United States;(2) The Ohio State University Medical Center;(3) The Ohio State University;(4) The Ohio State University Comprehensive Cancer Center.

PO5-09-12 Unraveling the Intricacies of Racial Disparities in Breast Cancer in Brazil. Jesse Lopes da Silva (1) Andreia Cristina De Melo (1) Mariana Espirito Santo Rodrigues (1) Lucas Zanetti de Albuquerque (1) Luiz Claudio Santos Thuler (1)
PO5-10-02 Neighborhood deprivation index and time to initiation in patients with metastatic breast cancer. Sneha Rajendran (1) Dianxu Ren (1) Marina Petruzzi (1) Margaret Rosenzweig (2) (1) University of Pittsburgh Medical Center; (2) University of Pittsburgh School of Nursing, PITTSBURGH, Pennsylvania, United States.

PO5-10-03 A Translational Epidemiologic Approach to Understand Disparities in Triple Negative Breast Cancer: Integrating Germline Genomics, Genetic Ancestry, and Neighborhood Disadvantage. Neha Goel (1) Alexandra Hernandez (2) Susan Kesmodel (3) Erin Kobetz (4) Nipun Merchant (5) Timothy Rebbeck (6) (1) University of Miami Department of Surgery; (2) Sylvester Comprehensive Cancer Center, University of Miami Health System; (3) University of Miami DeWitt Daughtry Dept. Surgery; (4) University of Miami; (5) University of Miami Miller School of Medicine; (6) Dana Farber Cancer Institute.

PO5-10-04 Rare to Care: Assessing Awareness and Health Disparity Factors Related to Inflammatory Breast Cancer in the Primary Care Setting. Gayathri R Devi (1) Lawrence Greenblatt (2) Rashmi Saincher (3) Valerie Keck (4) Beau Blass (5) Sarah Weaver (6) Alexandra Bennion (7) Anh Tran (8) (1) Department of Surgery, Duke University School of Medicine; Duke Consortium for Inflammatory Breast Cancer, Duke Cancer Institute, Durham, North Carolina, United States; (2) Duke University School of Medicine; Northern Piedmont Community Care, Durham, North Carolina, United States; (3) Duke Primary Care, North Carolina, United States; (4) Duke Outpatient Clinic, Durham, North Carolina, United States; (5) Duke University School of Medicine; (6) Duke University School of Medicine, Durham, North Carolina, United States; (7) Trinity College of Arts and Sciences, Duke University, North Carolina, United States.

PO5-10-06 A Pilot Study for Clinical Research Nurse Navigation at an Urban NCI-Designated Comprehensive Cancer Center. Lizzie Huckaby (1) Maisey Ratcliffe (1) Madison Canning (1) Demetria Smith-Graziani (2) Kevin Kalinsky (3) Manali Bhave (4) (1) Winship Cancer Institute, Emory University; (2) Dept of Hematology and Medical Oncology, Emory University School of Medicine; (3) Winship Cancer Institute at Emory University, Atlanta, Georgia, United States; (4) Emory University School of Medicine, Atlanta, Georgia, United States.


PO5-10-08 Clinical Value of Molecular Targets and Genome-Targeted Cancer Therapies Recommended by the National Comprehensive Cancer Network for Advanced Breast Cancer. Ariadna Tibau (1) Thomas J. Hwang (2) Jerry Avorn (3) Aaron Kesselheim (3) (1) Program On Regulation, Therapeutics, And Law (PORTAL) Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women’s Hospital and Harvard Medical School; (2) Cancer Innovation and Regulation Initiative, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States; (3) Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

PO5-10-10 Disparities in Work RVUs for Breast and Prostate Cancer Operations. Noah Khosrowzadeh (1) Kyle Chambers (1) Matthew Gompels (1) Cyrus Washington (2) Jessica Meshman (3) (1) University of Miami Miller School of Medicine;(2) Sylvester Cancer Center;(3) University of Miami.


PO5-11-01 Audit of multidisciplinary team meetings for improving breast cancer care. Kanika Sharma (1) Gopal Puri (1) (1) AIIMS, New Delhi, New Delhi, Delhi, India.

PO5-11-03 Associations among BMI and patient-reported body image dissatisfaction after breast reconstruction. Sara Bouhali (1) Nassima Noufail (1) Tzuan Chen (2) Mary Catherine Bordes (3) Greg Reece (4) Mia Markey (5) Fatima Merchant (6) Deert Kopra (3) (1) University of Houston, Sugar Land, Texas, United States;(2) University of Houston;(3) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;(4) MD Anderson Cancer Center / Department of Plastic and Reconstructive Surgery;(5) The University of Texas at Austin, Austin, Texas, United States;(6) University of Houston, Houston, Texas, United States.


PO5-11-05 Fertility, sexuality and other unmet needs of young breast cancer survivor during and at the end of treatment in France : a national qualitative study by the French Network of Cancer
PO5-11-06 Initial Results from a Cohort Study on the Impact of Breast Cancer on Employment in Mexican Patients. Arantxa Ramirez-Cisneros (1) David G Gonzalez-Sanchez (2) Daniela Vazquez-Juarez (3) Alejandra Platas (4) Alejandra Platas (5) Fernanda Mesa-Chavez (6) Giovanni M. Carrillo (2) Cynthia Villarreal-Garza (2)
(1) Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey;(2) Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Mexico;(3) Breast Cancer Center, Hospital Zambrano Hellion TecSalud;(4) Instituto Nacional de Cancerologìa;(5) Breast Medical Oncology Department, Instituto Nacional de Cancerologìa, Mexico;(6) Hospital Zambrano Hellion - TecSalud, Tecnologico de Monterrey, Nuevo Leon, Mexico.

PO5-11-07 Short- and long-term treatment-related effects on physical health in breast cancer survivors. Clara Bodelon (1) Matthew Masters (2) Lauren McCullough (1) Alpa Patel (1) Lauren Teras (1)
(1) American Cancer Society;(2) American Cancer Institute.

PO5-11-08 Assessing practice patterns of antidepressant medication and tamoxifen use among patients with hormone receptor-positive breast cancer. Mariah Ondeck (1) Bennett Osantowski (1) Nerea Lopez-Lia (2) Wei Wei (3) Alexandra Murray (1) Amanda Maggiotto (1) Halle Moore (3) Erin Roesch (4)
(1) Cleveland Clinic Foundation;(2) Cleveland Clinic Foundation, Cleveland, Ohio, United States;(3) Cleveland Clinic;(4) Cleveland Clinic, Ohio, United States.

(1) Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico;(2) Coordinacion de Universidad Abierta, Innovacion Educativa y Educacion a Distancia, CUAEEED-UNAM;(3) Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, Mexico;(4) Centro de Mindfulness Monterrey;(5) Yale University School of Medicine, New Haven, Connecticut, United States;(6) Tecnologico de Monterrey, Nuevo Leon, Mexico.

PO5-11-10 Quality of life in Brazilian women with early breast cancer on adjuvant endocrine therapy. Danielle Santos (1) Cristiano Souza (2) Maria Cristina Magalhães (3) Daniela Pereira (4) Fernanda Moura (5) Sulene Oliveira (6) Anna Luiza Galvão (7) Bruno Souza (8) Amanda Castro (9) Monalisa
(1) University Of Miami, Florida, United States;(2) university of miami;(3) University Of Miami;(4) University of Miami DeWitt Daughtry Dept. Surgery;(5) University of Miami Department of Surgery;(6) University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States;(7) University of Miami;(8) University of miami.

PO5-11-12 The use of wearable sensors and patient-reported outcomes in breast cancer research: A literature survey. Kelly Dumais (1) Adam Jagodinsky (1) Saima Khakwani (1) Rebecca Bonaker (1) Bryan McDowell (1) Kristen Sowalsky (1)
(1) Clario.

PO5-12-01 Characteristics of Patients Served by Participants in a Survivorship Navigator Learning Collaborative. Tamara Hamlish (1) Talia Holzman Castelllands (1)
(1) University of Illinois at Chicago, Chicago, USA, Illinois, United States.

PO5-12-02 Landscape analysis of oncology nutrition research among patients being treated for breast cancer. Kim Robien (1) Heather Wopat (1)
(1) Milken Institute School of Public Health, George Washington University.

PO5-12-03 Cardiovascular Toxicities in Breast Cancer Survivors. Victoria Ayodele (1) Emily Sherry (1) Marcela Mazo-Canola (2)
(1) UT Health Science Center San Antonio;(2) Mays Cancer Center, San Antonio, Texas, United States.

PO5-12-05 A Retrospective Study of the Rate of Cognitive Impairment and Influencing Factors during Postoperative Endocrine Therapy for Breast Cancer. Akari Murakami (1) Mayuko Aono (2) Kaho Utsunomiya (3) Kumiko Okujima (2) Kana Takemoto (2) Megumi Takaoka (2) Erina Kusakabe (2) Kana Taguchi (2) Kanako Nishiyama (2) Yoshiaki Kamei (2) Yasutsugu Takada (2) Hitoshi Tanimukai (4)
(1) Ehime University Hospital, Ehime, Japan, Japan;(2) Department of Hepato-Biliary-Pancreatic Surgery and Breast Surgery,Ehime University Graduate School of Medicine;(3) Matsuyama Red Cross Hospital,
PO5-12-06 Minimization of treatment toxicity/side effects and their impact on quality of life (QoL) in patients (pts) with ER+/HER2- metastatic breast cancer (mBC). Sarah Sammons (1) Jane Meisel (2) Kelly Shanahan (3) Timothy Pluard (4) Fumiko Chino (5) Dario Trapani (6) Dominic Carroll (7) Monica Kozlowski (7) Elizabeth Attias (7) Nicole Kuderer (8).

(1) Dana-Farber Cancer Institute, Boston, Massachusetts, United States; (2) Winship Cancer Institute, Atlanta, Georgia, United States; (3) Metavivor Research and Support, Inc, Annapolis, MD; (4) Saint Luke’s Cancer Institute, University of Missouri, Kansas City, Missouri, United States; (5) Memorial Sloan Kettering Cancer Center, New York, New York, United States; (6) European Institute of Oncology, IRCCS, University of Milano, Milan, Lombardia, Italy; (7) Sermonix Pharmaceuticals; (8) Advanced Cancer Research Group.

PO5-12-07 Analyzing Patient Experiences with Adjuvant Hormone Therapy for Early Breast Cancer Treatment via NLP/ML on Social Media: Symptoms and Their Mitigation. Sameet Sreenivasan (1) Chao Fang (1) Emuella Flood (1) Natasha Markuzon (1) Jasmine Sze (1)

(1) AstraZeneca.

PO5-12-08 QTc prolongation as Adverse Effect of CDK4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. Bruno Carvalho (1) Pedro Cotta Abrahão Reis (2) Alice Marinho (3) Ana Carolina Comini (4) Debora Xavier (5) Beatriz Mella S. Pessoa (6) Felipe Batalini (7)

(1) Faculdade de Medicina de Barbacena, Lavras, Minas Gerais, Brazil; (2) Universidade Federal do Rio de Janeiro - UFRJ; (3) Federal University of the State of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil; (4) A.C. Camargo Cancer Center, Brazil; (5) Universidade Federal do Para; (6) Federal University of Amazonas, Manaus, Amazonas, Brazil; (7) Mayo Clinic.


(1) Houston Methodist Hospital; (2) Houston Methodist Neal Cancer Center, Houston, Texas, United States; (3) Houston Methodist Dr. Mary and Ron Neal Cancer Center, Houston, Texas, United States; (4) MD Anderson Cancer Center; (5) Houston Methodist Hospital, Houston, Texas, United States.

PO5-12-10 Withdrawn


(1) O’Neal Comprehensive Cancer Center at the University of Alabama, Birmingham, Alabama, United States; (2) The University of Alabama at Birmingham; (3) UAB; (4) University of Alabama at Birmingham/O’Neal Comprehensive Cancer Center, Birmingham, Alabama, United States; (5) University of Alabama at Birmingham, Birmingham, Alabama, United States.
(1) Duke Cancer Institute, Durham, North Carolina, United States; (2) Duke Cancer Institute, Duke University; (3) Mercer University; (4) Duke University Hospital; (5) Duke Cancer Institute, Durham, North Carolina, United States; (6) Duke University; (7) Duke University, Durham, North Carolina, United States.

PO5-13-01 An App-Based Approach to Monitor Chemotherapy Symptoms. Opher Globus (1) Tal Sella (2) Amit Itay (1) Tali Shapira (1) Raisa Gold (1) Tami Modiano (1) Cecilia Oedegaard (1) Maya Krikli (1) Michal Bakalenik-Gavry (1) Beatrice Shaham (1) Alex Galper (1) Einav Nili-Gal Yam (3)
(1) Sheba Medical Center, Israel; (2) Sheba Medical Center, Tel Aviv, Israel; (3) Sheba Medical Center.

PO5-13-02 BRCA mutational profiles of endocrine-resistant breast cancer. Emelie Karlsson (1) Caroline Schagerholm (2) Stephanie Robertson (1) Hosein Toosi (3) Emmanouil Sifakis (4) Johan Hartman (5)
(1) Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; (2) Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; (3) Division of Computational Science and Technology, KTH Royal Institute of Technology and Science for Life Laboratory; (4) Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; (5) Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.

(1) BIOMARK DIAGNOSTIC SOLUTIONS, Canada; (2) The Metabolomics Innovation Centre; (3) BIOMARK DIAGNOSTICS; (4) Asper Clinical Research Institute, St. Boniface Hospital; (5) Department of Biological Sciences, University of Alberta; (6) Cancer Care Manitoba.

PO5-13-04 Breast Cancer Index (BCI) results from a HER2 low breast cancer community cohort of operable stage I-II hormone receptor positive (HR+) breast cancer. Milana Dolezal (1) Mark Pegram (2)
(1) Stanford Healthcare, Emeryville, California, United States; (2) Stanford School of Medicine.

PO5-13-05 Comparison of whole exome, whole transcriptome genomic profiling and targeted sequencing with 50-gene panels. Snehal Thakkar (1) David Hall (1) Jess Hoag (1) Cynthia Flannery (1) Nishitha Therala (1) Anson Tharayanil (1) Jesse Ortenbald (2) Gebra Cuyun Carter (1) Gargi Basu (1)
(1) Exact Sciences; (2) Stratevi.

PO5-13-06 Classifying HER2-low breast cancer using a combination of ERBB2 mRNA expression and altered genes. Gargi Basu (1) Niru Chennagiri (1) Turgut Dogruluk (1) David Hall (1) Jess Hoag (1) Cynthia Flannery (1) Snehal Thakkar (1) Melanie Palomares (1) Frederick Baehner (2) Lajos Pusztai (3)
(1) Exact Sciences; (2) Exact Sciences, SAN FRANCISCO, California, United States; (3) Yale School of Medicine, Cancer Center, New Haven, Connecticut, United States.

PO5-13-07 Prediction of recurrence in triple negative breast cancer patients after receiving neoadjuvant


PO5-13-09 Clinical usage of a CLIA accredited protein/phosphoprotein assay for breast cancer: Primary usage cases and significant findings in the HER2- setting. Claudius Mueller (1) Brian Corgiat (1) Emanuel Petricoin (2) Kayla Sparks (1) Joyce O’Shaughnessy (3) Chelsea Gawryletz (4) Matthew Schwartz (5) Justin Davis (6) (1) Theralink Technologies;(2) George Mason University;(3) Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas, United States;(4) UHealth, Fort Collins, Colorado, United States;(5) Comprehensive Cancer Centers of Neveda;(6) Theralink Technologies, Inc.


PO5-13-11 Quantitative Assessment of HER2 Expression in Intraductal Neoplasms of the Breast. Nay Nwe Nyein Chan (1) haiying Zhan (2) Revekka Khaimova (3) Thazin Aung (4) Charles Robbins (5) Patricia Gaule (2) David Rimm (4) (1) Yale School of Medicine, New Haven, Connecticut, United States;(2) Yale University;(3) Alexion, AstraZeneca Rare Disease;(4) Yale University, New Haven, Connecticut, United States;(5) Yale.

POS5-14-01 Weight loss and omega-3 polyunsaturated fatty acid intervention in overweight and obese peri- and postmenopausal women with increased breast cancer risk modifies the gut microbiome and is associated with circulating biomarkers. Katherine L. Cook (1) Erin Giles (2) Amy Kreutzjans (3) Shahid Umar (4) Christie Befort (4) Bruce Kimler (5) Stephen Hursting (6) Carol Fabian (7) (1) Wake Forest University School of Medicine;(2) University of Michigan, Ann Arbor, Michigan, United States;(3) University of Kansas Medical Center, Kansas City, Kansas, United States;(4) University of Kansas Medical Center;(5) University of Kansas Medical Center, Kansas City, Kansas, United States;(6) University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States;(7) University of Kansas Cancer Center, Kansas City, Kansas, United States.

POS5-14-02 Diagnostic leukapheresis to increase CTC detection rate in breast cancer patients after 5 years of adjuvant endocrine treatment. Noortje Verschoor (1) Jaco Kraan (1) Johanna Zuetenhorst (2) Mijntje Vastbinder (3) Jan Drooger (4) Stefan Sleijfer (1) Saskia M Wilting (1) John WM Martens (5) Agnes Jager (6) (1) Erasmus MC Cancer Institute, Rotterdam, The Netherlands;(2) Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Rotterdam/ Schiedam, the Netherlands;(3) Department of Medical Oncology, IJssel Hospital, Capelle aan den IJssel, the Netherlands;(4) Department of Internal Medicine, Breast Cancer Center South Holland South, Iekia Hospital, Rotterdam, The Netherlands;(5) Erasmus MC Cancer Institute, Rotterdam, The Netherlands, Rotterdam, Zuid-Holland, Netherlands;(6) Erasmus MC Institute, Rotterdam, The Netherlands, Netherlands.

POS5-14-03 Analytical Validation of the StemPrintER Assay in Patients with Breast Cancer. Catie Cronister (1) Brock Schweitzer (1) Hannah Gilmore (2) Tyler Nielsen (3) (1) Oncocyte Corporation;(2) University Hospitals Cleveland Medical Center;(3) Oncocyte.

POS5-14-04 FTIR Spectroscopy Analysis of Lipid Region: Distinguishing Breast Cancer from Benign Breast Diseases Using PCA-SVM. Juliana Pereira (1) Alinne Faria (2) Izabella Ferreira (3) Letícia Santos (4) Donizeti Santos (4) Marcelo Maia (5) Ohanna Costa (6) Raul Freitas (6) Carlos Paiva (7) Yara Maia (2) (1) Federal University of Uberlandia, Uberlândia, Minas Gerais, Brazil;(2) Federal University of Uberlândia, UFU, MG, Brazil;(3) Federal University of Uberlandia;(4) Federal University of Uberlândia;(5) Faculty of Computing, Federal University of Uberlandia;(6) Brazilian Synchrotron Light Laboratory (LNLS);(7) Barretos Cancer Hospital, Brazil.

POS5-14-05 Circulating tumor DNA fraction correlates with residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer patients. Naing Lin Shan (1) Billie Gould (2) Kim Blenman (3) Julia Foldi (4) Pan Du (5) Frank Zhang (2) Myles Walsh (2) Lajos pusztai (6)
PO5-14-06 **Transcriptomics-based drug screening in 3D ex vivo patient-driven breast cancer model and patient biopsy for personalized therapy.** Yueyun Zhang (1) Carlos Henrique Venturi Ronchi (2) Giovanna Ambrosini (3) Yuanlong Liu (4) Patrick Aouad (5) Daria Matvienko (3) Christoph Merten (3) Cathrin Brisken (6) (1) Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Vaud, Switzerland; (2) Swiss Federal Institute of Technology Lausanne (EPFL); (3) Swiss Federal Institute of Technology in Lausanne (EPFL); (4) SOPHiA GENETICS; (5) Hospital Ophthalmic Jules-Gonin; (6) ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.

PO5-14-07 **Detection of SPEN mutations in advanced breast cancer by circulating tumor cell-free DNA.** Charles Dai (1) Haley Barnes (1) Arielle Medford (2) Annika Putur (1) Jennifer Keenan (3) Beverly Moy (1) Seth Wander (4) Ryan Corcoran (1) Aditya Bardia (5) (1) Massachusetts General Hospital; (2) Massachusetts General Hospital Cancer Center / Dana Farber Cancer Institute; (3) Massachusetts General Hospital Cancer Center; (4) Massachusetts General Hospital, Boston, Massachusetts, United States; (5) Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.

PO5-14-08 **External Reproducibility of PD-L1 IHC 22C3 pharmDx on Breast Cancer Specimens at CPS ≥ 1 and CPS ≥ 10 Cutoffs.** Lori Steiner (1) Joseph Barreto (2) Emily Olander (1) Donna Kell (1) Siena Tabuena-Frolli (1) Monika Polewski (1) (1) Agilent Technologies, Inc., Carpinteria, California, United States; (2) Agilent Technologies, Inc., Carp, California, United States.

PO5-14-09 **Does transcriptome based DEPTH2 score reflect intratumor heterogeneity in breast cancer patients?** Kohei Chida (1) Rongrong Wu (2) Arya Mariam Roy (3) Takashi Ishikawa (4) Kazuaki Takabe (5) (1) Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center; (2) Roswell Park Comprehensive Cancer Center; (3) Roswell Park Comprehensive Cancer Center, Amherst, New York, United States; (4) Tokyo Medical University; (5) Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

PO5-14-10 **Dynamics and prognostic value of subtype specific TROP2 expression in matched pair samples of primary (PBC) and metastatic breast cancer (MBC) tissues.** Thomas Deutsch (1) Ralph Wirtz (2) Stefan Stefanovic (3) Andreas Hartkopf (4) Hans-Peter Sinn (5) Andreas Schneeweiss (6) Markus Wallwiener (1) (1) Heidelberg University Hospital, Germany; (2) STRATIFYER Molecular Pathology GmbH, Germany; (3) Mannheim University Hospital, Germany; (4) Tuebingen University Hospital, Germany; (5) Pathologie, Universitätsklinikum, Germany; (6) National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany.
PO5-14-11 Leveraging a pharmacokinetic/pharmacodynamic (PK/PD) model to guide dose optimization of palbociclib (palbo) in combination with vepedegrant. Brian Jermain (1) Derek Yang (2) Weiwei Tan (2) Julia Perkins-Smith (3) Justin Hoffman (1) Jason Williams (1) (1) Pfizer Inc.; (2) Pfizer Inc., La Jolla, California, United States; (3) Pfizer Inc.

PO5-14-12 XCL1 as a new potential biomarker for response to palbociclib in estrogen receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer patients. Mara Serena Serafini (1) Maroua MANAI (2) Victor Arrieta (3) Nadia Bayou (4) Elisabetta Molteni (5) Amanda Kaylan Strickland (1) Letizia Pontilillo (6) Eleonora Nicolò (7) Laura Munoz Arcos (8) Youbin Zhang (9) Ami N. Shah (10) Wenan Qiang (10) Carolina REDUZZI (6) Massimo Cristofanilli (6) (1) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; (2) Weill Cornell Medicine, NY, New York, United States; (3) Northwestern University, Chicago, Illinois, United States; (4) Faculty of Medicine-University of Tunis El Manar, Department of Human Genetics/Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; (5) Ospedale Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale; (6) Weill Cornell Medicine; (7) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; (8) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, New York, United States; (9) Northwestern Medicine Northwestern University, Chicago, Illinois, United States; (10) Northwestern University.

PO5-15-01 Prospective Biomarker Assessment of Cardiotoxicity Among Ethnically Diverse Women with Early Breast Cancer. Shahzaad Jahangier (1) Rubina Qamar (1) Maharaj Singh (2) Vinay Thohan (3) James Weese (1) Bijoy Khandheria (4) Anna Kamke-Jordan (5) (1) Advocate Aurora Health; (2) Aurora research Institute, Milwaukee, Wisconsin, United States; (3) Mission Health; (4) Advocate Health; (5) Advocate Aurora Research Institute.

PO5-15-02 Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA. Elisabetta Molteni (1) Carolina REDUZZI (2) Andrew Davis (3) Lorenzo Foffano (4) Arielle Medford (5) Katherine Clifton (3) Whitney L. Hensing (6) Marko Velimirovic (7) Ami N. Shah (8) Laura Munoz Arcos (9) Charles S. Dai (10) Jennifer C. Keenan (11) Ellysia Denault (12) William Gradishar (13) Giuseppe Damante (14) Amir Behdad (15) Lorenzo Gerratana (16) Fabio Puglisi (17) Cynthia Ma (18) Aditya Bardia (19) Massimo Cristofanilli (2) (1) Department of Medicine, University of Udine, Italy/Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA; (2) Weill Cornell Medicine; (3) Washington University in St Louis School of Medicine; (4) Department of Medicine, University of Udine; (5) Massachusetts General Hospital Cancer Center / Dana Farber Cancer Institute; (6) Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; (7) Cleveland Clinic; (8) Northwestern University; (9) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, New York, United States; (10) MGH Cancer Center; (11) Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Boston, MA 02114, USA; (12) Massachusetts General Hospital; (13) Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States; (14) Institute of Human Genetics, University of Udine; (15) Pathology and Laboratory medicine, Cleveland Clinic; (16) Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy; (17) National Cancer Institute, Centro di Riferimento Oncologico (CRO), IRCCS; (18) Washington University in St. Louis, St. Louis, Missouri, United States; (19) Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.
PO5-15-03 *Neutrophil-lymphocyte ratio and absolute lymphocyte count, inflammatory markers, may predict lymph node metastasis in elderly patients with operable breast cancer.* Emi Tokuda (1) Midori Morita (2) Akihiko Shimomura (3) Yoshiya Horimoto (4) Yukino Kawamura (5) Yumiko Ishizuka (4) Katsutoshi Sekine (6) Sayaka Obayashi (7) Yuki Kojima (8) Toru Higuchi (9) (1) Department of Medical Oncology, Fukushima Medical University; (2) Division of Endocrine & Breast Surgery, Kyoto Prefectural University of Medicine; (3) Department of Breast and Medical Oncology, National Center For Global Health And Medicine, Japan; (4) Department of Breast Oncology, Juntendo University; (5) Dept. of Breast and Medical Oncology, National Center for Global Health and Medicine; (6) Medical Oncology Center, Saitama City Hospital; (7) Department of General Surgical Science, Gunma University; (8) National Cancer Center Hospital; (9) Breast Surgery Unit, Japanese Red Cross Saitama Hospital.

PO5-15-04 *MammaPrint index predicts neoadjuvant chemosensitivity in patients with HR+HER2-early-stage breast cancer in the real-world evidence FLEX study.* Joyce O'Shaughnessy (1) Lajos pusztai (2) Cathy Graham (3) Pat Whitworth (4) Peter Beitsch (5) Cynthia Osborne (6) Rakhshanda Rahman (7) Andrea Menicucci (8) William Audeh (9) FLEX Investigators’ Group (10) (1) Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas, United States; (2) Yale School of Medicine, Cancer Center, New Haven, Connecticut, United States; (3) Emory University; (4) Nashville Breast Center; (5) Dallas Surgical Group; (6) Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, Texas, United States; (7) Texas Tech University Health Sciences Center; (8) Agendia Inc; (9) Agendia Inc.; (10) Agendia.

PO5-15-05 *Clinical and genomic landscape of ERBB2 and ERBB3 mutated breast cancer.* Nadeem Bilani (1) Jacqueline Tao (2) Anton Safonov (3) Dana Casey (4) Joshua Drago (5) Mehnaj Ahmed (6) Barbara Acevedo (6) Komal Jhaveri (5) Jorge Reis-Filho (7) Mark Robson (3) Eneda Toska (8) Ariella Hanker (9) Carlos Arteaga (10) Sarat Chandarlapaty (11) Hanna Y Wen (6) Pedram Razavi (5) (1) Icahn School of Medicine at Mount Sinai Morningside-West; (2) New York Presbyterian-Weill Cornell, New York, NY, USA; (3) Memorial Sloan Kettering Cancer Center, New York, United States; (4) University of North Carolina at Chapel Hill; (5) Memorial Sloan Kettering Cancer Center, New York, New York, United States; (6) Memorial Sloan Kettering Cancer Center; (7) AstraZeneca, Gaithersburg, Maryland, United States; (8) Johns Hopkins University School of Medicine, Baltimore, Maryland, United States; (9) UT Southwestern Medical Center, Dallas, Texas, United States; (10) UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, Texas, United States; (11) Memorial Sloan Cancer Center, New York, New York, United States.

PO5-15-06 *NVIGEN X® Comprehensive Liquid Biopsy for Sensitive ctDNA, Circulating Tumor Cells (CTC), and Protein Detection in Breast Cancer: Next-Generation Sequencing, Patient Case Studies, and Clinical Implications.* Aihua Fu (1) Minh Ton (1) Kevan Wang (1) Weiwei Gu (1) Henry Jin (1) Nuzhat Shaikh (2) Sasha Madan (2) Shreya Perepa (2) Tianhong Li (3) Minetta Liu (4) Heather Parsons (5) George Sledge (6) Fauzia Riaz (2) (1) NVIGEN Inc.; (2) Stanford University; (3) UC Davis Medical Center; (4) Natera, Austin, Texas, United States; (5) Dana Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts, United States; (6) Stanford University, Stanford, California, United States.

PO5-15-07 *Integrative proteomics, phosphoproteomics, and RNA profiling revealed novel timeline-dependent vulnerabilities in HER2-positive breast cancer.* Christina Wei (1) Lixin Yang (1) Krystine
PO5-15-08 **Role of next-generation sequencing testing in metastatic breast cancer.** Kashmira Wani (1) Manasi Godbole (2) Brigid Jacob (1) Kylie Springer (3) Vrushali Dabak (2) (1) Henry Ford Health; (2) Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, United States; (3) Henry Ford Health System, Detroit, Michigan, United States.

PO5-15-09 **DNA damage induced necroptosis predicts response to radioimmunotherapy.** Anna Goddard (1) Qinhong Wang (2) Minguk Cho (2) Lynn Lerner (2) Gaorav Gupta (3) (1) University of North Carolina, North Carolina, United States; (2) University of North Carolina; (3) University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

PO5-15-10 **Plasticity marker FOXC1 expression accurately predicts efficacy of Adjuvant Tamoxifen + Chemotherapy in reducing all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096).** Partha Ray (1) Tania Ray (2) Clive Taylor (3) Robert Hussa (2) (1) Private Practice, Evanston, Illinois, United States; (2) Onconostic Technologies, Inc.; (3) USC.

PO5-15-11 **A Novel Biosignature to Predict Radiation Therapy Response in Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Surgery.** Troy Bremer (1) Karuna Mittal (1) Chirag Shah (2) Frank Vicini (3) Steven Shivers (4) Charlotte Wadsten (5) (1) PreludeDx; (2) Cleveland Clinic, Ohio, United States; (3) GenesisCare; (4) PreludeDx, St Johns, Florida, United States; (5) Dept of Surgery, Sundsvall Hospital, Sweden.

PO5-15-12 **Spatial immune correlates of response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial.** Matthew Kearney (1) Hua Guo (2) Rami Vanguri (3) Qi Wang (2) Eileen Connolly (4) (1) Saint Luke's Cancer Specialists-South; (2) Columbia University Irving Medical Center; (3) Children's Hospital of Philadelphia; (4) Columbia University Irving Medical Center, New York, New York, United States.

PO5-16-01 **Clinicogenomic analysis reveals genomic associations of brain metastatic tropism in breast cancer.** Anton Safonov (1) Deborah Smith (2) Emanuela Ferraro (3) Juncho Shen (2) Ishaan Khatri (4) Rahul Kumar (5) Julia An (2) Mark Robson (1) Sarat Chandarlapaty (6) Adrienne Boire (2) Nikolaus Schultz (2) Nelson Moss (7) Luke Pike (2) Pedram Razavi (7) (1) Memorial Sloan Kettering Cancer Center, New York, United States; (2) Memorial Sloan Kettering Cancer Center; (3) Memorial Sloan Kettering Cancer Center/Breast Medicine Service, New York City, New York, United States; (4) The Warren Alpert Medical School of Brown University; (5) University of Miami; (6) Memorial Sloan Cancer Center, New York, New York, United States; (7) Memorial Sloan Kettering Cancer Center, New York, New York, United States.

PO5-16-02 **Investigating survivin as a novel target for immunotherapy in diverse breast cancer patients.** Alina Hamilton (1) Qichen Wang (2) Sarah Soppe (2) Melissa Troester (3) Yara Abdou (4)
PO5-16-03 **RT LAMP assay for the subtyping of breast cancer.** In Hee Lee (1) Byeongju Kang (2) Jeeyeon Lee (3) Jin Hyang JUNG (3) Ho Yong PARK (3) Nora Jee-Young PARK (4) Ji-Young PARK (4) Eun Ae KIM (2) Jieun KANG (2) Yee Soo Chae (5) Soo Jung Lee (1)
(1) Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital;(2) Kyungpook National University Chilgok Hospital;(3) Department of Breast & Thyroid Surgery, Kyungpook National University Chilgok Hospital;(4) Department of Pathology, Kyungpook National University Chilgok Hospital;(5) Department of Oncology/Hematology, Kyungbok National University, Chilgok Hospital, Daegu, Republic of Korea, Republic of Korea.

PO5-16-04 **Tissue-informed personalized MRD detection assay may outperform tumor-informed fixed panel strategy in Triple Negative Breast Cancer (TNBC).** Shunying Li (1) Wei Gao (2) Ning Fu (2) Wuqiang Cao (2) Xiaoling Zeng (2) Xinhua Du (2) Qiang Liu (1)
(1) Sun Yat-sen Memorial Hospital, Sun Yat-sen University;(2) GenePlus-Beijing.

PO5-16-05 **Integrating Circulating Tumor Cells (CTCs) and Cell-free DNA (cfDNA) Signatures for Monitoring Treatment Response in Stage III/IV Inflammatory Breast Cancer.** Sridevi Addanki (1) Salyna Meas (1) Vanessa Sarli (1) Abdulkader Almosa (1) Wendy Woodward (2) Dhruvajyoti Roy (1) Anthony Lucci (3)
(1) MD Anderson Cancer Center;(2) UT MD Anderson Cancer Center, Houston, Texas, United States;(3) MD Anderson Cancer Center, Houston, Texas, United States.

PO5-16-06 **Prophylactic Neurokinin-1 Receptor Antagonist Use Pre- and Post- Choosing Wisely Initiative among Women with Breast Cancer.** Shweta Kamat (1) Britny Brown (1) Steven Cohen (1) Ami Vyas (1)
(1) University of Rhode Island.

PO5-16-07 **Unveiling the Landscape of PD-L1 Expression and Tumor-Infiltrating Lymphocyte Subtypes in Advanced Triple-Negative Breast Cancer.** Alexssandra dos Santos (1) Jesse da Silva (1) Lucas De Albuquerque (1) Antônio Lucas Araújo Neto (1) Cecilia Silva (1) Luana Cerva (2) Isabele Small (1) Cicera Marcelino (3) Paula Batista (4) Maria Aparecida do Carmo Rego (3) Maria Amélia Borba (3) Lucas Zanetti de Albuquerque (5)
(1) Brazilian National Cancer Institute, Rio de Janeiro, Brazil;(2) Brazilian National Cancer Institute, Piauí, Brazil;(3) MSD Brazil, Sao Paulo, Brazil;(4) MSD Brazil, Santa Catarina, Brazil;(5) Brazilian National Cancer Institute, Rio de Janeiro, Rio de Janeiro, Brazil.

PO5-16-08 **Breast cancer in men: 15 years of experience in an oncology reference center in northern Mexico.** Fernando Peña (1) Javier A. Martínez-Moyano (2) Francisco Alvarado-Villarreal (3) Carlos Salazar-Mejía (3) David Hernández-Barajas (3) Oscar Vidal-Gutiérrez (2)
(1) Centro Universitario Contra el Cáncer, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico;(2) Oncology Service, Centro Universitario Contra el Cáncer, Hospital Universitario “Dr. José Eleuterio González”, Faculty of Medicine, Universidad Autónoma de Nuevo León., Nuevo Leon, Mexico;(3) Centro Universitario Contra el Cáncer, Hospital Universitario, Universidad Autónoma de Nuevo León.
PO5-16-09 **Associations of age, body mass index, diabetes and hypertension with relative dose intensity among women receiving anthracycline- and/or taxane-based chemotherapy for invasive breast cancer.** Heather Wopat (1) Annette Aldous (2) Adam Ciarleglio (2) Kendall Anderson (3) Kim Robien (4)

(1) George Washington University Department of of Exercise Science and Applied Nutrition;(2) George Washington University Department of Biostatistics and Bioinformatics;(3) George Washington University Cancer Center;(4) Milken Institute School of Public Health, George Washington University.


(1) Department of Women's Health, University Hospital Tuebingen, Germany;(2) Department for Gynecology and Obstetrics, Ulm University;(3) Department of Women's Health, Tuebingen University;(4) Diagnostic and Interventional Neuroradiology, Tuebingen University;(5) Department of Radiology, Freiburg University;(6) Department of Radiology, Ulm University;(7) Universitäts-Frauenklinik Tübingen, Eberhard Karls University, Germany;(8) Universitätsklinikum Tübingen;(9) Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen;(10) Department for Gynecology and Obstetrics, Freiburg University;(11) Department Gynecology and Obstetrics, University of Ulm, Ulm, Baden-Wurttemberg, Germany;(12) Research Institute for Women's Health, University of Tuebingen, Tuebingen, Germany;(13) Women’s Clinic, University Clinics Tuebingen, Germany.


(1) Department for Gynecology and Obstetrics, Ulm University;(2) Department of Women's Health, University Hospital Tuebingen, Germany;(3) Breast Center, University Hospital Ulm, Department of Women’s Health, Ulm, Baden-Wurttemberg, Germany;(4) University hospital Ulm, Department for obstetrics and gynecology, Ulm, Baden-Wurttemberg, Germany;(5) University hospital Ulm, Department for obstetrics and gynecology;(6) Department of Obstetrics and Gynecology, University Hospital Ulm, Germany;(7) University hospital Ulm, Ulm, Baden-Wurttemberg, Germany;(8) Breast Center, University Hospital Ulm, Department of Women’s Health;(9) Department of Women's Health, Tuebingen University;(10) Research Institute for Women's Health, University of Tuebingen, Tuebingen, Germany;(11) Department Gynecology and Obstetrics, University of Ulm, Ulm, Baden-Wurttemberg, Germany;(12) Women’s Clinic, University Clinics Tuebingen, Germany.

PO5-16-12 **EFFICACY AND TOLERABILITY OF METRONOMIC CHEMOTHERAPY (mChT) WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND CAPECITABINE (CMX) IN PATIENTS WITH HEAVILY PRETREATED ADVANCED BREAST CANCER. RESULTS FROM A MULTICENTER RETROSPECTIVE STUDY..**

Cristina Saavedra (1) María Gion (2) Alfonso Cortés (3) Patricia Cortez (4) Laia Garrigós (5) José Manuel Pérez-García (6) Gabriele Antonarelli (7) Javier Cortés (8)

(1) Hospital Universitario Ramón y Cajal, Madrid (Spain);(2) Hospital Universitario Ramón y Cajal;(3) Hospital Universitario Ramón y Cajal, Madrid (Spain); ONCARE;(4) IOB Institute of Oncology, Madrid, Spain;(5) International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Hospital
PO5-17-01 **Pre-treatment tumor infiltrating lymphocytes are associated with higher likelihood of pathologic complete response among black women with TNBC receiving neoadjuvant chemoimmunotherapy.** Sarah Wood (1) Ji-Hoon Lee (2) Yuan Gao (2) Xiaoxian Li (2) Jane Meisel (3) (1) Emory University, Decatur, Georgia, United States; (2) Emory University; (3) Winship Cancer Institute, Atlanta, Georgia, United States.

PO5-17-02 **Triple-negative breast cancer as an untraceable tumor compared to other immunohistochemical subtypes: a cross-sectional study.** Morgana Silva (1) Afonso Nazário (2) Vanessa Sanvido (3) (1) Universidade Federal de São Paulo - Unifesp; (2) Universidade Federal de São Paulo; (3) Universidade Federal de São Paulo/Hospital do Coração (Hcor).

PO5-17-03 **Relative Dose Intensity and Protraction of Neoadjuvant Chemotherapy in Early-Stage and Locally Advanced Breast Cancer: A collaborative multicenter analysis in Colombia.** Alejandro Murillo (1) Andres Acevedo (2) Santiago Betancur (3) Mariana Borras-Osorio (4) Isabel Munevar (5) William Mantilla (6) Luis Pino (7) (1) Institute of Cancer Carlos Ardila Lulle, Fundación Santa Fe de Bogotá; (2) nternal Medicine Department, Fundación Santa Fe de Bogotá - Faculty of Medicine, Universidad del Bosque - Alprocrates Think Tank, OxLER Lab; (3) Alprocrates Think Tank, OxLER Lab; (4) Fundación Cardioinfantil, Bogota, Distrito Capital de Bogota, Colombia; (5) Fundación Cardioinfantil / Hospital Militar Central, Bogota, Distrito Capital de Bogota, Colombia; (6) Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center CTIC; (7) Institute of Cancer Carlos Ardila Lulle, Fundación Santa Fe de Bogotá - Alprocrates Think Tank, OxLER Lab -.

PO5-17-04 **Tolerability of pertuzumab in older adults with HER2 positive breast cancer: A single institution experience.** Nicole Williams (1) Austin Warmbier (2) Dureti Doto (3) Marilly Palettas (4) Julie Stephens (1) Dionisia Quiroga (1) Kai Johnson (1) Ashley Pariser (5) Mathew Cherian (6) Sagar Sardesai (1) Daniel Stover (7) Margaret Gatti-Mays (5) Robert Wesolowski (8) Bhuvana Ramaswamy (9) (1) The Ohio State University Comprehensive Cancer Center; (2) Scribe American; (3) The Ohio State University; (4) The Ohio State University Wexner Medical Center; (5) The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States; (6) The Ohio State University Comprehensive Cancer Center, Dublin, Ohio, United States; (7) Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States; (8) James Cancer Hospital and the Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States; (9) Ohio State University Comprehensive Cancer Center.

PO5-17-05 **Recommendations of a panel of experts from the Brazilian Society of Mastology on breast and axilla clipping: when, how and for whom?.** Henrique Couto (1) Augusto Hassan (2) Dalton
(1) King Faisal Specialist Hospital and Research Center, Riyadh, Ar Riyad, Saudi Arabia;(2) King Faisal Specialist Hospital & Research Center;(3) College of Medicine, Alfaisal University;(4) King Faisal Specialist Hospital & Research Center, Saudi Arabia;(5) King Faisal Specialist Hospital and Research Center, Saudi Arabia.

PO5-17-07 MUCINOUS BREAST CARCINOMA: REAL WORLD DATA IN A REFERENCE CENTER IN SÃO PAULO. Marina Fleury De Figueiredo (1) ANDRE MATTAR (2) Felipe Cavagna (3) Ana Lígia Minatel da Silva (3) Rafaela nadai (3) Juliana Medeiros de Oliveira (3) Luma Fleury de Figueiredo (4)
(1) Womens’ Health Hospital, São Paulo, Brazil, São Paulo, Sao Paulo, Brazil;(2) HOSPITAL PEROLA BYINGTON, São Paulo, Sao Paulo, Brazil;(3) Womens’ Health Hospital, São Paulo, Brazil;(4) Pará’s State University (Belém-PA, Brazil).

PO5-17-08 Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer. Matthew Kurian (1) Marcus Trybula (2) Kanchi Patell (2) Gregory Guzik (3) Seunghee Margevicius (4) Pingfu Fu (5) Alberto Montero (6) James Martin (7)
(1) St. Elizabeth Cancer Center;(2) University Hospitals/Seidman Cancer Center;(3) University Hospitals;(4) Case Comprehensive Cancer Center;(5) Case Western Reserve University, Department of Population and Quantitative Health Sciences;(6) UH/Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA;(7) University Hospitals/Seidman Cancer Center, Cleveland, Ohio, United States.

PO5-17-10 PERFORMANCE AND OUTCOMES OF THE 70-GENES SIGNATURE (MAMMAPRINT™) IN A POPULATION WITH MIDDLE INCOME – REAL WORLD STUDY (AGEMA-BRA). Fabio Mansani (1)  Ruffo Freitas-Junior (2)
(1) UNIVERSIDADE ESTADUAL DE PONTA GROSSA, Ponta Grossa, Parana, Brazil;(2) Federal University of Goias & Araújo Jorge Cancer Hospital, Goiânia, Goias, Brazil.

PO5-17-11 STRATIFICATION OF HIGH GENOMIC RISK IN THE GENETIC SIGNATURE OF 70 GENES (MAMMAPRINT™) IN REAL WORLD ANALYSIS (AGEMA-BRA). Fabio Mansani (1)  Ruffo Freitas-Junior (2)
(1) UNIVERSIDADE ESTADUAL DE PONTA GROSSA, Ponta Grossa, Parana, Brazil;(2) Federal University of Goias & Araújo Jorge Cancer Hospital, Goiânia, Goias, Brazil.

(1) Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil;(2) Federal University of Rio Grande do Sul, Porto Alegre, Brazil, Rio Grande do Sul, Brazil;(3) Oncoclinicas, Brazil;(4) Post Graduation Program of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil;(5) caisal-UNICAMP, Sao Paulo, Brazil;(6) Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil;(7) Faro Stat Solutions, Porto Alegre, Brazil;(8) Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Rio Grande do Sul, Brazil;(9) Faculty of Medical Sciences, Department of Pathology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.

PO5-18-01 Cancer Detection Rate Meta-Analysis Comparison of Contemporary Dense-Breast Supplemental Screening Modalities. Martin Tornai (1)  James Hugg (2)  Bradley Patt (3)  Chin-Tu Chen (4)  Eduardo Santos (3)  Alaattin Erkanli (5)  Samantha Morrison (6)  Matthew Covington (7)
(1) Duke University, Durham, North Carolina, United States;(2) SmartBreast Corp, Texas, United States;(3) SmartBreast Corp, California, United States;(4) University of Chicago;(5) Duke University Hospital;(6) Duke University;(7) University of Utah, Utah, United States.

PO5-18-03 A Randomized Controlled Trial to Evaluate the Safety and Efficacy of 1 cm versus 2 cm resection margins in Phyllodes Tumours of the Breast - An Exploratory Study. Vandhana Rajgopal (1) Anita Dhar (2) Kamal Kataria (3) Piyush Ranjan (4) ANURAG SRIVASTAVA (5) (1) All India Institute of Medical Sciences, New Delhi, India; (2) AIIMS, New Delhi, New Delhi, Delhi, India; (3) AIIMS New Delhi; (4) AIIMS New Delhi; (5) Subharti Institute of Cancer Management and Research, MEERUT, Uttar Pradesh, India.

PO5-18-04 Effect of Digoxin on clusters of circulating tumor cells in patients with metastatic breast cancer (DICCT). Marcus Vetter (1) Bich Doan Ngyuen-Sträuli (2) Ilona Krol (3) Alexander Ring (4) Angela Kohler (5) Francesca Castro-Giner (3) Maren Vogel (6) Cvetka Grasic Kuhar (7) Fabienne Schwab (6) Viola Heinzelmann-Schwarz (6) Gabriela Kuster Pfister (8) Walter Weber (9) Christian Kurzeder (10) Nicola Aceto (3) (1) Cancer Center Baselland, Liestal, Basel-Landschaft, Switzerland; (2) Department of Gynecology, University Hospital Zurich, University of Zurich; (3) Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich; (4) Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich; (5) Center of Oncology and Hematology, Medical University Clinic, Kantonsspital Baselland; (6) Department of Gynecology and Gynecologic Oncology, University Hospital Basel, University of Basel; (7) Institute of Oncology Ljubljana, Slovenia; (8) Department of Cardiology, University Hospital Basel, University of Basel; (9) Breast Center, University Hospital of Basel, Switzerland; (10) Breast Center, University Hospital of Basel, Basel, Switzerland, Basel-Stadt, Switzerland.

PO5-18-05 Assessment of the Potential of Photon mini-GRID Therapy for Pre-operative Partial Breast Cancer Treatment. Angela Corvino (1) Tim Schneider (2) Jeremi Vu-Bezin (3) Youlia Kirova (4) Yolanda Prezado (5) (1) Institute Curie, Université Paris-Saclay, France; (2) Université Paris-Saclay; (3) Institut Gustave Roussy; (4) Institut Curie, Paris, Ile-de-France, France; (5) Institute Curie.

PO5-18-06 On-going phase 1A clinical trial of A01, a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88) in patients with advanced malignancy. Katherine Tkaczuk (1) Paula Rosenblatt (2) Ranee Mehra (3) Katherine Scilla (3) Nancy Tait (4) Binbin Yue (5) Ginette Serrero (6) (1) University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; (2) University of Maryland School of Medicine; (3) University of Maryland School of Medicine, Baltimore, Maryland, United States; (4) University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States; (5) A&G Pharmaceutical, Columbia, Maryland, United States; (6) A&G Pharmaceutical Inc, Columbia, Maryland, United States.
PO5-18-07 **A Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits TNBC Lung Metastases.** Lillian Hsu (1) Patrick Nasarre (2) Julie Siegel (2) Eleanor Hilliard (2) Rupak Mukherjee (2) Nancy Klauber-Demore (2)
(1) MUSC;(2) Medical University of South Carolina.

PO5-18-09 **Anthracycline-free neoadjuvant therapy with nab-paclitaxel and carboplatin in non-luminal breast cancer: a single-arm phase II trial.** Deyue Liu (1) Li Zhu (1) Jiayi Wu (2) Wei Wang (3) Shuning Ding (3)
(1) Department of Breast and Thyroid Surgery, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine;(2) Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine;(3) Shanghai General Hospital.

(1) Breast Center, University of Rostock, Germany;(2) Universitätsfrauenklinik am Klinikum Südost Rostock;(3) Filderklinik, Germany;(4) Breast Center;(5) Johanniter-Krankenhaus Genthin-Stendal, Germany;(6) Albertinen-KH Hamburg, Germany;(7) University Hospital Essen, Germany;(8) Klinikum Esslingen, Germany;(9) Clínica Universidad de Navarra, Madrid, Spain;(10) Univ.Prof. Priv.Doz. Dr. Florentia Pintinger, Austria;(11) German Breast Group, Germany;(12) Cancer Registry Norway;(13) San Raffaele Hospital Milan, Italy.

PO5-18-11 **Use of DiviTum®TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interaction assessment in ER/PR positive metastatic breast cancer.** Mariya Rozenblit (1) Adriana Kahn (2) Guannan Gong (3) Amy Williams (4) Lajos pusztai (5)
(1) Yale Cancer Center, New Haven, Connecticut, United States;(2) Yale Cancer Center, Yale University;(3) Yale University;(4) Biovica International AB;(5) Yale School of Medicine, Cancer Center, New Haven, Connecticut, United States.

PO5-18-12 **Can we cure de novo oligometastatic stage IV HER2+ breast cancer with multimodality therapy? (CHLOE).** Mariya Rozenblit (1) Nathalie Wiesendanger (2) Kelly Shanahan (3) Christine Hodgdon (4) Peter Gershkovich (2) Mehra Golshan (5) Meena Moran (6) maryam lustberg (1) Lajos pusztai (7)
(1) Yale Cancer Center, New Haven, Connecticut, United States;(2) Yale University;(3) Metavivor Research and Support;(4) GRASP - Guiding Researchers & Advocates To Scientific Partnerships, Baltimore, Maryland, United States;(5) Yale School of medicine, Yale cancer center;(6) Yale;(7) Yale School of Medicine, Cancer Center, New Haven, Connecticut, United States.

PO5-19-02 I-PREPARE: International Prospective Registry on Pre-pectoral breast Reconstruction (EUBREAST 11R-NCT 05817175). Rosa Di Micco (1) Maggie Banys-Paluchowski (2) Maria-Joao Cardoso (3) Jana de Boniface (4) Bahadir M. Gulluoglu (5) Orit Kaidar-Person (6) Thorsten Kühn (7) Maurizio Bruno Nava (8) Philip Poortmans (9) Shelley Potter (10) Nicole Rotmensz (11) Marc Thill (13) Luzia Travado (14) Walter Weber (15) Oreste Davide Gentilini (16) (1) Breast Surgery Unit, San Raffaele University and Research Hospital (Milan, Italy), Italy;(2) Department of Obstetrics and Gynecology, Asklepios Hospital Barmbek, Germany;(3) Breast Unit, Champalimaud Research and Clinical Centre, Champalimaud Foundation (Lisbon, Portugal); Faculdade de Medicina da Universidade de Lisboa (Lisbon, Portugal);(4) Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, and Department of Surgery, Capio St. Göran’s Hospital, Stockholm, Stockholms Lan, Sweden;(5) Marmara University School of Medicine, Department of Surgery, Turkey;(6) Breast Cancer Radiation Therapy Unit, Sheba Medical Center (Ramat Gan, Israel); Sackler School of Medicine, Tel-Aviv University (Tel-Aviv, Israel);(7) Department of Gynecology, Hospital Esslingen, Germany;(8) Breast unit, Valduce Hospital, Como, Italy; G.Re.T.A. Foundation, Milan, Italy;(9) Department of Radiation Oncology, Iridium Network and University of Antwerp, Belgium;(10) Bristol Medical School;(11) Breast Surgery Unit, San Raffaele University and Research Hospital (Milan, Italy);(12) Europa Donna Slovenia, Slovenia;(13) Agaplesion Markus Krankenhaus Frankfurt, Frankfurt, Hessen, Germany;(14) Champalimaud Clinical & Research Center, Champalimaud Foundation, Lisbon, Portugal;(15) Breast Center, University Hospital of Basel, Switzerland;(16) Breast Surgery Unit, San Raffaele University Hospital, Italy.


PO5-19-05 A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients with Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer. Jose Bazan (1) Joanne Mortimer (2) Yun-Rose Li (3)
(1) City of Hope Comprehensive Cancer Center, Duarte, California, United States;(2) City of Hope, Duarte, California, United States;(3) City of Hope Comprehensive Cancer Center.

(1) UT Southwestern, Dallas, Texas, United States;(2) MS KCC;(3) UT Southwestern Medical Center, Dallas, Texas, United States;(4) University of Texas Southwestern Medical Center;(5) University of Texas Southwestern Medical Center, Dallas, Texas, United States;(6) Oncoclínicas, Brazil;(7) Cedars-Sinai Medical Center;(8) The Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, USA, Los Angeles, California, United States;(9) Robert W. Franz Cancer Research Center and Alliance, Portland, Oregon, United States;(10) Providence Cancer Institute, Portland, Oregon, United States;(11) Providence;(12) UTSSW;(13) Oncotherapeutics;(14) Lerner Research Institute;(15) The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States;(16) Memorial Sloan Kettering Cancer Center.

(1) UT Southwestern, Dallas, Texas, United States;(2) Oncoclínicas, Brazil;(3) University of Texas Southwestern Medical Center;(4) University of Texas Southwestern Medical Center, Dallas, Texas, United States;(5) Cedars-Sinai Medical Center;(6) UTSSW;(7) The Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, USA, Los Angeles, California, United States;(8) UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER SIMMONS CANCER CENTER, Dallas, Texas, United States;(9) Oncotherapeutics;(10) Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States;(11) New Mexico Cancer Center;(12) Robert W. Franz Cancer Research Center and Alliance, Portland, Oregon, United States.
PO5-19-09 Trial in progress: A prospective randomized, controlled study to evaluate device efficacy for cutting and/or coagulation of tissue during mastectomy procedures. Jessica Montalvan (1) Ivan Marin (2) Logan Healy (2) Margarita Riojas-Barrett (2) Mary Bajomo (2) Elizabeth Bonefas (2) Alastair Thompson (3) Marco Maricevich (3) Sebastian Winocour (2) Stacey Carter (2) (1) Baylor College of Medicine, Texas, United States; (2) Baylor College of Medicine; (3) Baylor College of Medicine, Houston, Texas, United States.


PO5-19-11 A novel portable breast cancer screening method - initial institutional experience. Margarita Riojas-Barrett (1) Jessica Montalvan (2) Mary Bajomo (1) Ivan Marin (1) Quan Dang Nguyen (1) Karla A Sepulveda (2) Elizabeth Bonefas (1) Alastair Thompson (3) Stacey Carter (1) (1) Baylor College of Medicine; (2) Baylor College of Medicine, Texas, United States; (3) Baylor College of Medicine, Houston, Texas, United States.

PO5-19-12 Innovative Trial Design: ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL) - Multicentre Study. Karla Sepulveda (1) Ashley Roark (1) Sagar Dhamne (1)
POS-20-01 **SENTINOT2- Use of superparamagnetic iron oxide tracer to avoid unnecessary sentinel lymph node biopsies.** Mary Bajomo (1) Ivan Marin (1) Jessica Montalvan (2) Margarita Riojas-Barrett (1) Logan Healy (1) Elizabeth Bonefas (1) Steacy Carter (1) Alastair Thompson (3)

(1) Baylor College of Medicine; (2) Duke University; (3) Duke University, Durham, North Carolina, United States.


(1) Dana-Farber Cancer Institute, Boston, Massachusetts, United States; (2) University of North Carolina, Chapel Hill, North Carolina, United States; (3) Memorial Sloan Kettering Cancer Center; (4) University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States; (5) Cleveland Clinic Brain Tumor and Neuro-Oncology Center; (6) Dana-Farber Cancer Institute, Boston, Massachusetts, United States; (7) University of Alabama at Birmingham/O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States; (8) Duke Cancer Institute, Durham, North Carolina, United States.

POS-20-03 **Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician's choice systemic therapy in subjects with breast cancer brain metastases.** Colette Shen (1) Yara Abdou (2) Linda Chen (3) Xiaming Tan (1) Gaorav Gupta (4) Mina Lobbous (5) Filipa Lynch (6) Erica Stringer-Reasor (7) Carey Anders (8)

(1) UNC Lineberger Comprehensive Cancer Center; (2) University of North Carolina, Chapel Hill, North Carolina, United States; (3) Memorial Sloan Kettering Cancer Center; (4) University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States; (5) Cleveland Clinic Brain Tumor and Neuro-Oncology Center; (6) Dana-Farber Cancer Institute, Boston, Massachusetts, United States; (7) University of Alabama at Birmingham/O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States; (8) Duke Cancer Institute, Durham, North Carolina, United States.


(1) University of Illinois Cancer Center; (2) NYU; (3) University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States; (4) University of Virginia; (5) University of Michigan; (6) University of Iowa Hospitals and Clinics; (7) University of Illinois; (8) Orlando Health; (9) Parkview; (10) Providence Cancer Institute; (11) Rutgers Cancer Institute of New Jersey; (12) University of Arizona; (13) University of Michigan Health West.
PO5-20-05 The FOR ME (Fostering Opportunities in Research through Messaging and Education) study: Using multiple qualitative methods to develop a culturally sensitive narrative intervention to promote equity in clinical trials. Neha Hippalgaonkar (1) Ryan Nguyen (1) Leslie Carnahan (2) Vida Henderson (3) Tigist Mersha (4) Eliza Cohn (3) Kauthar Salum (3) Ana Williams (4) Lolita Coleman (5) Beulah Brent (5) AnneMarie Murphy (6) Paris Thomas (6) Paramjeet Khosla (7) Kent Hoskins (1) (1) University of Illinois Chicago;(2) The University of Illinois at Chicago;(3) Fred Hutchinson Cancer Center;(4) University of Illinois at Chicago;(5) Sisters Working It Out;(6) Equal Hope;(7) Mt. Sinai Hospital.

PO5-20-06 Paraneoplastic cerebellar degeneration in anti-Yo antibody and HER2-positive metastatic breast carcinoma. You Kim (1) Alison Coogan (1) Andrea Madrigrano (1) (1) Rush University Medical Center.

PO5-20-07 A Case of Metastatic Breast Cancer to Soft Tissue of the Thigh. Rangel Melissa (1) Julia Alexieva (1) Alison Coogan (1) Lily Hussein (2) Elizabeth Marcus (2) Julie Wescler (2) (1) Rush University Medical Center;(2) John H. Stroger, Jr. Hospital of Cook County.

PO5-20-08 A Case of Multifocal Ductal Breast Carcinoma with Extension into Lobules and Concurrent Primary Colon Adenocarcinoma. Rabab Jafry (1) Hina Khan (2) Jessica Jones (3) (1) Aga Khan Medical University;(2) The University Health Science Center at Houston;(3) UT Health Houston, Houston, Texas, United States.

PO5-20-09 LOCOREGIONAL MANAGEMENT OF DE NOVO STAGE IV HORMONE-POSITIVE BREAST CARCINOMA AFTER CDK 4/6 INHIBITOR TREATMENT. Raye Angeli Abella (1) Rubi Li (1) (1) St. Luke’s Medical Center, Quezon City, National Capital Region, Philippines.

PO5-20-10 Treatment with CDK4/6 Inhibitor in a Patient with Metastatic Breast Cancer Causing Myelophthisis. Nikita Dahake (1) Jordan Senchak (2) Jalil Nasibli (2) Jason Incorvati (2) (1) Temple University, Philadelphia, Pennsylvania, United States;(2) Fox Chase Cancer Center.


PO5-20-12 A Case of Bilateral Breast Cancer in a patient on Ocrelizumab. Kriti Mehra (1) Mohamad Hejazi (2) (1) Saint Vincent Hospital, Worcester, Massachusetts, United States;(2) Hartford Healthcare Medical Group.

PO5-21-01 Carcinoma en cuirasse- a rare, but striking, cutaneous manifestation of metastatic breast cancer. Manasi Godbole (1) Kashmira Wani (2) Shereen Zia (2) Vrushali Dabak (1) (1) Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, United States;(2) Henry Ford Health.
PO5-21-02 Breast cancer screening based on physical breast examination: ITABERAÍ randomized trial. 
Ruffo Freitas-Junior (1) Danielle Rodrigues (2) Rosangela Corrêa (2) Leonardo Soares (2)
(1) Federal University of Goias & Araujo Jorge Cancer Hospital, Goiânia, Goias, Brazil; (2) Federal University of Goiás, Brazil.

PO5-21-03 Cosmetic assessment in the UNICANCER HypoG-01 trial: a deep learning approach.
(1) TheraPanacea, Paris, France; (2) Centre Jean Bernard - Clinique Victor Hugo - Institut inter-régional de Cancérologie (ILC) - CCS, 64 Rue de Degré, 72000 Le Mans, France; (3) Institut Gustave-Roussy, Département d’oncologie radiothérapie, Villejuif, France; (4) Institut Curie, Paris, Ile-de-France, France; (5) Centre Léon Bérard, Lyon, France; (6) Centre Eugène Marquis, Rennes, France; (7) ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France; (8) Institut de Cancérologie de Lorraine, France; (9) Département de radiothérapie, Centre Antoine Lacassagne, Nice, France; (10) Hôtel du Scorff, Lorient, France; (11) Centre Régional De Lutte Contre Le Cancer Georges-François Leclerc C.G.F.L, Dijon, France; (12) Centre Henri Becquerel, Rouen, France; (13) Centre Oscar Lambret, Lille, France; (14) Institut Godinot; (15) Institut de Cancérologie de l'Ouest (ICO) - Site d'Angers, Angers, France; (16) Paoli-Calmettes Institute, Marseille (France); (17) Institut Bergoniè; (18) CORT37, Chambry-lès-Tours, France; (19) Site Chénieux - Polyclinique de Limoges, Limoges, France; (20) ICM - Montpellier, Montpellier, France; (21) C.H. de Lens, Lens, France; (22) C.H. Intercommunal Créteil, Créteil, France; (23) Centre Gallilée, Lille, France; (24) Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; (25) Institut de cancerologie des haut de France, Beauvry, France; (26) Clinique Bordeaux Tivoli-Ducos, Bordeaux, France; (27) Centre Jean Perrin, Clermont-Ferrand, France; (28) Henri Mondor University Hospital, France; (29) Institut de Cancérologie de l'Ouest, ICO - René Gauduchau, Nantes, France; (30) Centre Francois Baclesse; (31) Centre Pierre Curie, Beauvry, France; (32) Gustave Roussy, Bureau Biostatistique et Epidémiologie, F-94805, VILLEJUIF France/Oncostat U1018, Inserm, Université Paris-Saclay, Ligue Contre le Cancer, F-94805, VILLEJUIF France; (33) Gustave Roussy, Villejuif, France; (34) UNICANCER, Unitrad, Paris, France; (35) CentraleSupelec. University of Paris-Saclay; (36) Gustave Roussy.

PO5-21-04 Leveraging Digital Twins for Patient Stratification and Treatment Optimization in geriatric oncology: A Breast Cancer Multivariate Clustering Analysis. Pierre HEUDEL (1) Mashal Ahmed (2) Felix Renard (2)
(1) centre leon berard; (2) Geodaisics.

PO5-21-05 An Endocrine Resistant-Related Gene Signature Revealing the Tumor Microenvironment to Predict the Prognosis of Hormone Receptor-Positive Breast Cancer Patients. Xiyu Kang (1) Jiaxiang Liu (1) Xin Wang (2)
(1) Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
PO5-21-06 **Pathway profiling for prediction of response to neoadjuvant Letrozole therapy in ER positive postmenopausal breast cancer: gaining new insights for targeted treatment.** Nadia de Gruil (1) Anne Florine de Groot (2) Yvonne Wesseling-Rozendaal (3) Diederick Keizer (3) Sigi Neerken (3) Judith Kroep (2) (1) Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands; (2) Leiden University Medical Center; (3) InnoSIGN, Netherlands.

PO5-21-07 **Mitomycin: its developmental role in the treatment of patients with BRCA - associated triple-negative early and locally advanced breast cancer.** Petr Krivorotko (1) Evgeniy Imyanitov, (2) Diana Enaldieva (3) Elena Zhiltsova (4) Anna Sokolenko (4) Laysan Shaikhelislamova, (5) Larisa Gigolaeva (3) Tengiz Tabagua (3) Alexander Komyakho (3) Kirill Nikolaev (3) Konstantin Zernov (3) Sergey Yerechshenko (3) Roman Pesotsky (3) Nikolay Amirov (3) Alexander Emelyanov (3) Viktoriya Mortada (3) Yana Bondarchuk (3) Vladislav Semiglashov (3) (1) N.N. Petrov National Medical Research Center of Oncology, Russia; (2) NMRC of Oncology named after N.N.Petrov of MoH of Russia, Saint Petersburg, Saint Petersburg City, Russia; (3) N.N. Petrov National Medical Research Center of Oncology; (4) NMRC of Oncology named after N.N.Petrov of MoH of Russia, Saint Petersburg City, Russia; (5) NMRC of Oncology named after N.N.Petrov of MoH of Russia, Russia.

PO5-21-08 **Real world experience with Carboplatin plus Nab-paclitaxel as neoadjuvant therapy in patients with early triple negative breast cancer.** Manuel Alva (1) Pablo Tolosa (2) Rodrigo Sánchez-Bayona (3) Laura Lema (1) Ainhoa Madariaga (4) Cristina González Deza (5) Lucia Parrilla (6) Cristina Martín-Arriscado (7) Luis Manso (8) Eva Ciruelos (9) (1) Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; (2) SOLTI Cancer Research Group, Barcelona, Spain; (3) Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; (4) 12 de Octubre University Hospital, Madrid, Spain; (5) Hospital 12 de Octubre; (6) Pathology department, Hospital Universitario 12 de Octubre, Madrid Spain; (7) Instituto de investigación Biomédica del Hospital Universitario 12 de Octubre I+12; (8) Hospital Universitario 12 de Octubre, Spain; (9) SOLTI Breast Cancer Research Group, Barcelona, Spain / Medical Oncology, Hospital Universitario, Spain.

PO5-21-09 **Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in HR+/HER2- metastatic breast cancer.** Aditya Bardia (1) Peter Schmid (2) Sara Tolaney (3) Frederik Marmé (4) Javier Cortés (5) Theresa Valdez (6) Hao Wang (7) Wendy Verret (7) Hope Rugo (8) (1) Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States; (2) Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, United Kingdom; (3) Dana-Farber Cancer Institute, Boston, Massachusetts, United States; (4) Med. Fakultät Mannheim der Universität Heidelberg, Germany; (5) International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; (6) Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey, US; (7) Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.; (8) Gilead; (7) Gilead Sciences
PO5-21-10 Efficacy and Safety of Alpelisib in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor: An Open-label, Multi-centre, Prospective, Single Arm Clinical Trial. Rik Van Severen (1) Anne-Sofie De Crem (2) Hava Izci (3) Laurence Slimbrouck (4) Isabelle Vanden Bempt (5) Hans Wildiers (5) Kevin Punie (6) Eline Naert (7) Ingeborg Hilderson (7) Ann Smeets (8) Ines Nevelsteen (9) Anne Deblander (5) Nynke Willers (4) Patrick Berteloot (5) Ignace Vergote (4) Sileny Han (10) Adriaan Vanderstichele (4) Giuseppe Floris (5) Christine Desmedt (11) Hannelore Denys (12) Patrick Neven (13) (1) Catholic University of Leuven, Belgium; (2) University of Ghent; (3) KU Leuven; (4) Catholic University of Leuven; (5) University Hospitals Leuven; (6) Leuven Cancer Institute, University Hospitals Leuven; (7) Medical Doctor; (8) Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; (9) Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium, Belgium; (10) University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium; (11) Laboratory for Translation Breast Cancer Research/KU Leuven, Leuven, Vlaams-Brabant, Belgium; (12) Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; (13) Universitair Ziekenhuis Leuven, Leuven, Vlaams-Brabant, Belgium.

PO5-21-11 Withdrawn

PO5-22-03 Influence of the surgical clip concerning the dose and volume of irradiated surrounding tissues including lung and heart in the planning of radiotherapy boost with conservative breast surgery with and without oncoplasty. Nilceana Freitas (1) PRISCILA WATANABE (2) Jean Paiva (3) CAROLINA BEZERRIL (3) MARCELO VALENTIM (4) Thais Gontijo (5) Flavia Araujo (5) Ruffo Freitas-Junior (6) (1) ARAUJO JORGE CANCER HOSPITAL & CEBROM, Goiania, Goias, Brazil; (2) Federal University of Goias, Brazil; (3) ARAUJO JORGE CANCER HOSPITAL & CEBROM, Brazil; (4) CEBROM; (5) ARAUJO JORGE CANCER HOSPITAL; (6) Federal University of Goias & Araujo Jorge Cancer Hospital, Goiânia, Goias, Brazil.

PO5-22-04 Genomic analysis of local recurrences following risk adapted breast radiotherapy in the IMPORT trials defines 'true recurrences' and 'new primaries'. Sara Lightowlers (1) Maria Roman-Escorza (2) Elena Provenzano (3) Judith Bliss (4) Jason Carroll (5) H Y Charlie Chan (6) Clare Griffin (7) Joanne Haviland (8) Monica Jefford (9) Anna Kirby (10) Navita Somaiah (11) Mark Sydenham (4) Jenny Tiley (12) John Yarnold (12) Charlotte Coles (13) Elinor Sawyer (14) (1) University of Cambridge, Cambridge, England, United Kingdom; (2) Kings College London, United Kingdom; (3) Cambridge University Hospitals NHS Trust, UK and Cambridge Biomedical Research Centre (NIHR), United Kingdom; (4) Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, England, United Kingdom; (5) CRUK Cambridge Institute and Precision Breast Cancer Institute, University of Cambridge, United Kingdom; (6) Department of Breast Surgery, Nuffield Health Cheltenham Hospital, United Kingdom; (7) Clinical Trials and Statistics Unit, Institute of Cancer Research, London, England, United Kingdom; (8) Queen Mary University of London, United Kingdom; (9) Independent Cancer Patient’s Voice, United Kingdom; (10) The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust; (11) The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, United Kingdom; (12) Institute of Cancer Research, United Kingdom; (13) University of Cambridge, United Kingdom; (14) School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy’s Cancer Centre, King’s College London, London, UK.

PO5-22-08 Comparison of long-term oncological outcomes in young women with breast cancer between BRCA-mutation carriers versus non-carriers: How genetic risk factors and tumor characteristics influence the prognosis. Damiano Gentile (1) Simone Di Maria Grimaldi (2) Andrea Sagona (2) Erika Barbieri (2) Alberto Bottini (2) Giuseppe Canavese (2) Giulia Caraceni (2) Shady Darwish (2) Corrado Tinterri (2) (1) IRCCS Humanitas Research Hospital, Italy;(2) IRCCS Humanitas Research Hospital.


PO5-22-10 Are contralateral prophylactic mastectomy rates impacted by ASBrS guidelines to offer germline genetic testing to all patients with breast cancer? Results from a large, prospective, single-institution cohort. Anna Weiss (1) Stephen Knapp (2) Danielle Braun (2) Brenna Barton (3) Monica McGrath (3) Samantha Stokes (2) Alison Laws (4) Laura Warren (3) Stefania Morganti (5) Filipa Lynce (6) Brittany Bychkovsky (7) Huma Rana (8) Dillon Davis (2) Jill Stopfer (8) Judy Garber (9) Tari King (10) (1) Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States;(2) Dana-Farber Cancer Institute;(3) Brigham and Women's Hospital;(4) Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center;(5) Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute of MIT and Harvard;(6) Dana-Farber Cancer Institute, Boston, Massachusetts, United States;(7) Comprehensive Breast Health Center, Brigham and Women's Hospital; Breast Oncology Program, Dana-Farber Brigham Cancer Center Division of Cancer Genetics and Prevention; Dana-Farber Cancer Institute; Harvard Medical School;(8) Dana Farber Cancer Institute;(9) Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute;(10) Division of Breast Surgery, Brigham and Women's Hospital, Breast Oncology Program, Dana-Farber/Brigham Cancer Center, Harvard Medical School, Boston, Massachusetts, United States.

PO5-22-12 Development and Validation of a Genomic Test to Predict Tumor Response of the Axillary Nodes after Neoadjuvant Chemotherapy (NAC) in Patients with HER2-negative Breast Cancer: Results of the AGO-35 trial. Florentia Peintinger (1) Thorsten Kühn (2) Hans-Christian Kolberg (3) Roland Reitsamer (4) Sabine Schmatloch (5) Elisa Sieghartsleitner (6) Lili Du (7) Andrea Berghold (8) W. Fraser Symmans (9)

(1) Univ.Prof. Priv.Doz. Dr. Florentia Peintinger, Austria; (2) Department of Gynecology, Hospital Esslingen, Germany; (3) Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany; (4) Breast Center, Paracelsus Medical University of Salzburg, Salzburg, Austria; (5) Brustzentrum Elisabeth-Krankenhaus Kassel, Germany; (6) Universitätsklinik für Frauenheilkunde und Geburtshilfe, Graz, Austria; (7) Department of Translational Molecular Pathology University of Texas MD Anderson Cancer Center; (8) Institut für Medizinische Informatik, Statistik und Dokumentation, Medizinische Universität Graz, Austria; (9) UT MD Anderson Cancer Center.


Michael Boland (12) Vivian Man (13) Ava Kwong (14) Fredrik Wärnberg (15)

(1) Dept of Surgery, Sahlgrenska Academy, Gothenburg University; (2) Department of Surgery, Sahlgrenska University Hospital, Sweden; (3) Sahlgrenska University Hospital; (4) Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden, Vastra Gotaland, Sweden; (5) Dept of radiology, Sahlgrenska Academy, Gothenburg University; (6) Department for Surgical Sciences, Uppsala University, Sweden; (7) Department of Surgical Sciences, Uppsala University; (8) Department of Surgery, Västmanland County Hospital, Västerås, Sweden; (9) Department of Oncology, Ryhov County Hospital, Jönköping, Sweden 7 Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; (10) Baylor College of Medicine, Houston, Texas, United States; (11) Department of Surgery, The Royal Marsden Hospital NHS Trust, London, United Kingdom; (12) Department of Breast Surgery, St Vincent’s University Hospital, Dublin 4, Ireland; (13) Department of Surgery, University of Hong Kong, Hong Kong SAR; (14) Department of Surgery, The University of Hong, Kong-Shen Zhen Hospital, China; (15) Gothenburg University, Sweden.

PO5-23-02 Targeted Axillary Dissection with Paramagnetic Marker Localization. Roland Reitsamer (1) Andreas Sir (2) Ernst Forsthuber (2) Florentia Peintinger (3)

(1) Breast Center, Paracelsus Medical University of Salzburg, Salzburg, Austria; (2) University Hospital Salzburg, Department of Senology, Paracelsus Medical University Salzburg, Austria; (3) Institute of Pathology, Medical University of Graz, Graz, Austria / Universitätsklinik für Frauenheilkunde und Geburtshilfe, Graz, Austria.
PO5-23-03 **Impact of prosthetic nipple reconstruction after mastectomy on quality of life.** Oreste Claudio Buonomo (1) Jonathan Caspi (2) Marco Materazzo (3) Marco Pellicciaro (3) Gianluca Vanni (3) (1) Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome (RM), Italy; (2) Ars Biomedica, Via Luigi Bodio, 58, 00191 Roma, Italy, Lazio, Italy; (3) Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome (RM), Italy.; Tel Aviv, Israel; (4) PhD Program in Applied Medical-Surgical Sciences, Department of Surgical Science, Tor Vergata University, Rome, RM, Italy.;

PO5-23-04 **Clinical utility of sentinel lymph node biopsy in women ≥ 70 years with early breast cancer – an international, retrospective multi-center cohort study.** Radhika Merh (1) Denise Vorburger (2) Ji-Jung Jung (3) Han-Byoel Lee (4) Marios Tasoulis (5) (1) The Royal Marsden NHS Foundation Trust, Worcester Park, England, United Kingdom; (2) Breast Cancer Unit, Comprehensive Cancer Center Zurich, University Hospital Zurich, Switzerland; (3) Seoul National Univ. Hospital, Surgery, Korea; (4) Seoul National University Hospital; (5) The Royal Marsden NHS Foundation Trust, London, England, United Kingdom.

PO5-23-05 **The Impact of Bi-Annual Diagnostic Imaging on Detecting Ipsilateral Breast Recurrence in Patients Undergoing Breast Conserving Surgery for Breast Cancer.** Pabel Miah (1) Laura Fiedler (1) Anthony Baez (1) Athanasios Svedalis (1) Alyssa Marmer (1) Charles DiMaggio (1) Linda Pak (1) Richard Shapiro (1) Karen Hiottis (1) Deborah Axelrod (1) Amber Guth (1) Freya Schnabel (2) (1) NYU Langone Health; (2) NYU Grossman School of Medicine, New York, New York, United States.

PO5-23-06 **Predictive Factors for Reconstructive Method and Outcomes in Mutation-Positive Breast Cancer Patients.** Shrayus Sortur (1) Jaytin Gupta (1) Christian Lava (2) Lauren Berger (2) Varsha Harish (3) Zoya Khan (1) Daisy Spoer (2) Lindy Rosal (2) Ian Greenwald (2) Lucy De La Cruz (4) David Song (3) Kenneth Fan (3) (1) Georgetown Univ SOM; (2) MedStar Georgetown University Hospital; (3) Georgetown University; (4) Medstar Georgetown University Hospital, Department of Breast Surgery.

PO5-23-07 **Withdrawn**

PO5-23-08 **Adenylosuccinate lyase is essential for proliferation and mitochondrial function of endocrine therapy resistant breast cancer cells.** Anil Yadav (1) Lu Jin (2) Robert Clarke (1) Surojeet Sengupta (1) (1) The Hormel Institute; (2) Hormel Institute/University of Minnesota.

PO5-23-09 **Metabolic alterations in Estrogen Receptor-positive breast cancer contributing to CDK4/6 resistance.**. Mayar Allam (1) Ahmet Coskun (2) Thomas Hu (3) Yuan Gu (4) Sunil Badve (5) Yesim Gokmen-Polar (5) (1) Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University; (2) Georgia Institute of Technology & Emory University; (3) Georgia Institute of Technology; (4) Department of Pathology&Laboratory Medicine, Emory University School of Medicine; (5) Emory University School of Medicine.
Development of a long-term in vitro assay able to identify compounds that can overcome resistance to CDK4/6 inhibitor plus endocrine therapy in ER+ HER2- breast cancer. Stephanie Kronstadt (1) Neil Umbreit (1) Matt Niederst (1) Rens Janssens (1) (1) Novartis Institutes for BioMedical Research.

Elevated linoleic acid levels in red blood cells membrane predicts response to neoadjuvant chemotherapy in breast cancer patients. Benjamin Walbaum (1) CÉSAR SÁNCHEZ (1) FRANCISCO ACEVEDO (1) (1) Pontificia Universidad Catolica de Chile.

Narazaciclib’s differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical models. Petros Kechagioglou (1) Debomita Chakraborty (1) Camille Dupont (1) Hajime Yurugi (1) Ute Distler (2) Stefan Tenzer (2) Alexey Chernobrovkin (3) Kristina Riegel (1) Julianne Mooz (1) Mahil Lamber (4) Volker Dötsch (4) Stephen Cosenza (5) Steven Fruchtmann (5) Krishnaraj Rajalingam (1) (1) Johannes Gutenberg University Medical Centre Mainz;(2) Institute of Immunology, University Medical Center Mainz;(3) Pelago Bioscience;(4) Goethe University, Frankfurt;(5) Onconova Therapeutics Inc.

Interferon-induced bone marrow stromal antigen 2 (BST2) is a functional tumor-initiating cell marker in triple-negative breast cancer. Eric Souto (1) Ping Gong (2) John Landua (2) Ram Srinivasan (2) Lacey Dobrolecki (2) Abhinaya Ganesan (2) Michael Lewis (1) (1) Baylor College of Medicine, Houston, Texas, United States;(2) Baylor College of Medicine.


PO5-24-07 HER2 EXPRESSION HETEROGENEITY PATTERN IN INVASIVE BREAST CARCINOMAS: FREQUENCY, DISTRIBUTION AND RELATION TO MORPHOLOGICAL VARIABLES. Angela Flavia Waitzberg (1) Lucas de Figueiredo Barbosa (2) Adilson Monteiro dos Santos Filho (2) Ana Luiza da Cruz (2) Lisandra Gonzalez Porta Nova (2) Karla Calaça Kabbach Prigenzi (2) (1) Universidade Federal de São Paulo, São Paulo, Sao Paulo, Brazil; (2) São Paulo Federal University.

PO5-24-08 Differential exploitation of Cation Transport Regulator homolog 1 (CHAC1) by Wild-type and mutant p53. VIKRANT MEHTA (1) HARISH CHANDER (2) (1) CENTRAL UNIVERSITY OF PUNJAB, San Antonio, Texas, United States; (2) National Institute of Biologicals, NOIDA, Uttar Pradesh, India.

PO5-24-10 Clinical significance and immune landscape analyses of the immune related genes based prognostic signature for HER2 positive breast cancer. Xiaofen Li (1) Wenfen Fu (2) Yushuai Yu (1) Jie Zhang (2) Chuangui Song (3) (1) Fujian Cancer Hospital; (2) Fujian Medical University Union Hospital; (3) Fujian Provincial Cancer Hospital.

PO5-24-11 An integrated approach for comprehensive molecular and tumor microenvironment characterization of invasive lobular carcinoma. Jason Mouabbi (1) Konstantin Chernyshov (2) Oleg Baranov (2) Vladimir Kushnarev (3) Polina Turova (2) Anna Butusova (4) Sofia Menshikova (5) Jessica Brown (3) Nikita Kotlov (5) Patrick Clayton (2) Krystle Nomie (5) Nathan Fowler (5) Debu Tripathy (1) (1) The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; (2) BostonGene, Corp.; (3) BostonGene; (4) BostonGene; (5) BostonGene Corp..

PO5-24-12 IRX5010, a Highly Selective RARγ Nuclear Receptor Agonist Compound Inhibits In Vivo Growth of Murine EMT-6 Triple Negative Breast Cancer and Human JIMT-1Her2+ Breast Cancer by Induction of Tumor-Infiltrating Effector Memory T-cells. Martin Sanders (1) Mary Topalovski (2) Vidyasagar Vuligonda (1) (1) Io Therapeutics, Inc., The Woodlands, Texas, United States; (2) Champions Oncology.

PO5-25-01 Treating liver metastases by reversing cell competition between metastatic cancer cells and hepatocytes. Katherine Lake (1) Sakshi Mohta (1) Clayton Smith (1) Venkata Repaka (1) Lily Xu (1) Kaitlyn Saunders (2) Vrushali Pandit (1) Emily Goff (1) Christine Zhang (1) Jacob Pena (1) Christine Hodgdon (3) Julia Maues (4) Elizabeth Chen (1) Isaac Chan (5) (1) UT Southwestern; (2) UT Southwestern, University of Texas at Dallas; (3) Grasp Cancer; (4) GRASP, Washington, District of Columbia, United States; (5) University of Texas Southwestern Medical Center.

PO5-25-02 Microenvironment based co-culture dependence of breast cancer and immune cell interactions on functional outcomes. Karen Norek (1) Jacob Kennard (2) Kenneth Fuh (1) Robert Shepherd (1) Kristina Rinker (3) Olesya Kharenko (4) (1) Syantra inc.; (2) Syantra inc., Alberta, Canada; (3) University of Calgary, Calgary, Alberta, Canada; (4) Syantra inc., Calgary, Alberta, Canada.

PO5-25-03 Immune cell infiltrate profiles in primary Triple Negative Breast Cancer and co-relation with treatment response and survival outcomes. Pooja Vaid (1) Devaki Kelkar (2) LS Shashidhara (3) C B Koppiker (4) Madhura Kulkarni (2)
PO5-25-04 Predictive value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with triple negative breast cancer treated with pembrolizumab. Ashley Schreier (1) Roberta Zappasodi (2) Inna Serganova (2) Laura Munoz Arcos (3) Xi Kathy Zhou (2) Massimo Cristofanilli (4) Eleni Andreopolu (5)
(1) Weill Cornell Medical College, New York, United States; (2) Weill Cornell/New York Presbyterian; (3) Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, New York, United States; (4) Weill Cornell Medicine; (5) New York Presbyterian/Weill Cornell Medical Center/Columbia University, New York, NY.

PO5-25-05 Crosstalk between adipocyte and tumor cells with ESR1 mutations via adipsin enhances tumor growth. Artem Belyakov (1) Kideok Jin (2)
(1) Albany College of Pharmacy and Health Sciences; (2) Albany College of Pharmacy and Health Sciences, Albany, New York, United States.

PO5-25-06 S100A4 blocking antibody suppresses metastasis through immune modulation. Jia-Shiun Leu (1) Hui Deng (2) Xiong Wei (2) Han Nhat Tran (1) Nourhan Abdelfattah (1) José M Benítez Salazar (1) Jose A Maldonado (3) Carlo D.D. Cristobal (4) Hyun-Kyoung Lee (4) Zhiqiang An (2) Ningyan Zhang (2) Kyuson Yun (1)
(1) Houston Methodist Research Institute; (2) Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center; (3) Houston Methodist Hospital; (4) Baylor College of Medicine.

PO5-25-07 A research impact assessment method to evaluate Susan G. Komen’s research funding impact on drugs approved for breast cancer treatment. Dana Brantley-Sieders (1) Lauren Leslie (2) Amy Dworkin (2) Kimberly Sabelko (3) Kari Wojtanik (4)
(1) Susan G. Komen, Mebane, North Carolina, United States; (2) Susan G. Komen; (3) Susan G. Komen, Dallas, Texas, United States; (4) Susan G. Komen®.

PO5-25-09 rs2242652 POLYMORPHISM OF THE hTERT GENE IN WOMEN WITH BREAST CANCER. Miriam Alvares (1) Elisa Mascarenhas (1) Joao Matos (2)
(1) OncoClinicas, Brasilia, Distrito Federal, Brazil; (2) OncoClinicas, Brazil.

(1) Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY; (2) Roswell Park Comprehensive Cancer Center; (3) Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY; (4) Division of Research, Kaiser Permanente Northern California, Oakland, CA; (5) Division of Research, Kaiser Permanente Northern California; (6) Kaiser Permanente Division of Research; (7) Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.
(1) Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, England, United Kingdom; (2) The Institute of Cancer Research, Clinical Trials and Statistics Unit; (3) University of Glasgow - Institute of Cancer Sciences, United Kingdom; (4) Outreach Research & Innovation Group Ltd, Manchester, England, United Kingdom; (5) Independent Cancer Patients' Voice; (6) Cambridge University Hospitals NHS Foundation Trust; (7) The University of Manchester.

(1) Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Norway; (2) KG Jebsen Center for Genome-directed therapy in Cancer, University of Bergen, Norway; (3) German Breast Group; (4) Institut für Pathologie, Philippus Universität Marburg und Universitätsklinikum Marburg (UKGM), Germany; (5) Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; (6) University Hospital Frankfurt, Germany; (7) AGO-B and HELIOS Klinikum Berlin Buch, Berlin, Germany; (8) Institut für Pathologie, Charité Berlin, Germany; (9) Institute of Pathology, Philippus-Universität Marburg (UKGM), Germany; (10) Breastcenter, Hospital Detmold/Ostwestfalen-Lippe, Germany; (11) Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, Switzerland; (12) Manchester Cancer Research Centre, University of Manchester, UK; (13) Universitätsklinikum Frankfurt, Germany; (14) Med. Fakultät Mannheim der Universität Heidelberg, Germany; (15) Department of Obstetrics and Gynecology, University Hospital Erlangen, Germany; (16) Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Hordaland, Norway; (17) Klinik für Gynäkologie und Geburtshilfe, Uniklinik RWTH Aachen, Germany; (18) Mammazentrum am Krankenhaus Jerusalem, Germany; (19) Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie und Geburtshilfe, Schleswig-Holstein, Germany; (20) Universitätsklinikum Hamburg-Eppendorf, Germany; (21) German Breast Group, Neu-Isenburg, Germany; (22) German Breast Group, Germany; (23) German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany, Germany.

Assessing the effect of multimodal therapy in massive fungating breast cancers without distant metastasis. Tamaki Tamanuki (1) Maki Namura (1) Tomoyoshi Aoyagi (1) Haruhito Sakata (1) Mika Iwai (1) Shinichirou Shimizu (2) Hiroshi Matsuzaki (1)
(1) Breast Surgical Oncology, Funabashi Municipal Medical Center; (2) Pathology, Funabashi Municipal Medical Center.

(1) National Institute of Cancer, Ciudad de Mexico, Distrito Federal, Mexico;(2) INSTITUTO NACIONAL DE CANCEROLOGIA;(3) Instituto Nacional de Cancerologia, Distrito Federal, Mexico;(4) Instituto Nacional de Cancerología;(5) National Institute of Cardiology Ignacio Chavez.

PO5-26-04 **The value of skin involvement in achieving of pCR in patients with locally advanced breast cancer.** Viktory Amosova (1) Alexander Petrovskiy (2) Oxana Trofimova (1) Mona Frolova (1) Alexey Rumyantsev (1)
(1) N.N. Blokhin National Cancer Research Center;(2) Federal State Budget Institution "National Medical Research Center of Oncology na N.N. Blochín" Ministry of Healthcare of Russian Federation, Russia.

PO5-26-05 **Machine learning-based risk prediction for late distant recurrence in young women with estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer.** Dong Seung Shin (1) Janghee Lee (2) Jong-Ho Cheun (3) Jun-Hee Lee (4) Yewon Shin (5) Soong June Bae (6) Eunhye Kang (7) Sunyoung Kwon (8) Han-Byoel Lee (9) Jai Min Ryu (10) Sung Gwe Ahn (6)
(1) Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of Korea;(2) Sacred Heart Hospital, Hallym University, Dongtan;(3) Seoul Metropolitan Government Seoul National University Boramae Medical Center;(4) Soonchunhyang University Seoul Hospital;(5) Dept. of Information Convergence Engineering, College of Information and Biomedical Engineering, Pusan National University, Busan, Republic of Korea;(6) Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Republic of Korea;(7) Seoul National Univ. Hospital, Surgery, Republic of Korea;(8) School of Biomedical Convergence Engineering, College of Information and Biomedical Engineering, Pusan National University, Yangsan, Republic of Korea;(9) Seoul National University Hospital;(10) Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam, Ulsan-gwangyoksi, Republic of Korea.

PO5-26-06 **Understanding patient experiences to inform future studies to reduce treatment burden in breast cancer.** Shelley Potter (1) Mhairi MacTier (2) Katherine Fairhurst (1) Jacqui Gath (3) Hilary Stobart (4) Stuart McIntosh (5)
(1) Bristol Medical School;(2) NHS Greater Glasgow and Clyde NHS Trust;(3) NA;(4) Independent Cancer Patients' Voice;(5) Queen's University Belfast.

PO5-26-08 *Caveats behind the improved outcomes observed in recent clinical trials for women with breast cancer: Korean breast cancer consensus meeting 2023.* Airi Han (1) Young-Joon Kang (2) Sei Hyun Kim (3) Eui Su Chae (4) Han Cho Kim (5) Kyong Hwa Park (6)
(1) Yonsei University Wonju college of Medicine; (2) Incheon St. Mary's Hospital; (3) Seoul National University; (4) Kyoung Pook University; (5) Soon Cheon Hyang University; (6) Korea University Anam Hospital, Republic of Korea.

PO5-26-09 *Digital image analysis and a novel set of cell line samples as aids in the development of a quantitative external quality assessment programme for Ki-67.* Andrew Dodson (1) Fitim Berisha (2) Dawn Wilkingsson (2) Lila Zabaglo (2) Suzanne Parry (2)
(1) UK NEQAS ICC & ISH, United Kingdom; (2) UK NEQAS ICC & ISH.

PO5-26-10 *Withdrawn*

PO5-26-11 *The Breast Cancer Research Foundation Drug Research Collaborative – A unique and innovative model for industry-funded, academically driven research to advance the field of breast cancer.* Unnati Jariwala (1) Dorraya El-Ashry (2) Judy Garber (3) Larry Norton (4)
(1) BCRF, Phoenix, Arizona, United States; (2) BCRF; (3) Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute; (4) Memorial Sloan Kettering Cancer Center.

PO5-26-12 *Optimizing Treatment Decisions in Microinvasive Ductal Carcinoma in Situ: Evaluating the Need for Surgical Axillary Staging.* Christian Lava (1) Karen Li (1) Lauren Berger (1) Daisy Spoer (1) Lindy Rosal (1) Austin Williams (2) Monika Masanam (3) Ian Greenwald (1) Jennifer Son (4) Lucy De La Cruz (5)
(1) MedStar Georgetown University Hospital; (2) Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States; (3) Medstar Georgetown University Hospital; (4) MedStar Georgetown/MedStar Montgomery, North Bethesda, Maryland, United States; (5) Medstar Georgetown University Hospital, Department of Breast Surgery.

PO5-27-01 *Comparison between the 7th and the 8th edition of TNM Staging System of American joint committee on Cancer(AJCC) for Breast Cancer Patients, diagnosed and treated at King Abdulaziz Medical City.* Nafisa Abdelhafiez (1) Abdulmohsen Alkushi (1) Lolwah Alriyees (1) MOHAMMAD ARABI (1) Faris Alsalamah (1) Emad Masudi (2) AHMAD OMAIR (1) Mohammad Alkaiyat (1) Hussam shehata (3)
(1) National Guard Health Affairs; (2) king abdulaziz university for health sciences; (3) King Abdulaziz Medical City, riyadh, Ar Riyadh, Saudi Arabia.
(1) Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States;(2) Duke University, North Carolina, United States;(3) Trinity College of Arts and Sciences, Duke University, North Carolina, United States;(4) Biomedical Engineering, Duke University, North Carolina, United States;(5) Mechanical Engineering, Baylor University;(6) Department of Radiation Oncology, Duke University School of Medicine; Duke Cancer Institute;(7) Department of Surgery, Duke University School of Medicine; Duke Consortium for Inflammatory Breast Cancer, Duke Cancer Institute, Durham, North Carolina, United States.

(1) UT Health San Antonio, San Antonio, Texas, United States;(2) University of Minnesota;(3) University of Minnesota, Minneapolis, Minnesota, United States;(4) Ohio State University, Columbus, Ohio, United States;(5) Masonic Cancer Center, University of Minnesota, Minnesota, United States.

PO5-27-04 The epidemiological profile and lifestyle of non-village indigenous women from Amazonas, Brazil and the likely impact on breast cancer mortality. MARIA RISELDA VINHOTE DA SILVA (1) LILIAN CRISTINA DE SOUZA GUIMARÃES (2) Afonso Nazário (3) MARIANA GUIMARAES DE OLIVEIRA CASTRO (4)
(1) UEA;(2) Hospital Universitario da Universidade Federal do Amazonas;(3) Universidade Federal de São Paulo;(4) UFAM.

PO5-27-05 Computational design and validation of a novel peptide-drug conjugate for treatment of triple negative breast cancer. Francine Liu (1) Andrew Zhai (1) Ozge Yoluk (1) Aron Broom (1) Tracy Stone (1) Glenn Butterfoss (1) Serban Popa (1) Tianyu Li (1) Lucas Siow (1) Christopher Ing (1) David White (1)
(1) ProteinQure, Inc, Ontario, Canada.

PO5-27-06 Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins. Zdravka Medarova (1) Neil Robertson (1) Subrata Ghosh (1) Andreas Varkaris (2) Peter Caravan (3) Susan Duggan (1)
(1) TransCode Therapeutics, Inc.;(2) Massachusetts General Hospital, Boston, Massachusetts, United States;(3) Athinoula A. Martinos Center for Biomedical Imaging, MGH, HMS.

PO5-27-07 A novel ROR1 inhibitor CPD86 suppresses Triple-Negative Breast Cancer cells via regulation of AKT/GSK3β pathway. Tram Ta (1) Victoria Reed (2) Nikhil Chandra (2) Nick Dwyer (2) Norman Fultang (3) Shradheya Gupta (4) Indrakant Singh (4) Bela Peethambaran (2)
(1) Saint Joseph's University, Philadelphia, Pennsylvania, United States;(2) Saint Joseph's University;(3) University of the Sciences;(4) University of Dehli.

PO5-27-08 Cytotoxicity and motility inhibitory effect of FA-Hep-CuS nanoparticles on breast cancer cells. David Arreola (1)
(1) Texas A&M University.


PO5-27-10 Next generation antibody drug conjugates: Multi-payload conjugates targeting multiple mechanisms of cell killing. Marco Lobba (1) Devin Trinter (1) Maxwell Nguyen (1) Daniel Gutierrez (1) Samantha Brady (1) Chanez Symister (1) Andrew Lau (1) Richard Kendall (1) Saurabh Johri (1) Matthew Francis (2) (1) CatenaBio; (2) University of California, Berkeley.

PO5-27-11 A COMPARATIVE STUDY OF DIAGNOSTICS MADE BY FINE NEEDLE ASPIRATION (FNA) BIOPSY VERSUS TRU-CUT FOR BREAST PATHOLOGY IN A ONE STOP CLINIC PROGRAM IN MEDELLIN, COLOMBIA. Sara Gil (1) Carlos Agudelo (2) Jorge Castaño (2) Melissa Naranjo (2) Clara Piedrahita (2) Daniel Wilches (2) Kelly Corredor (3) (1) Ayudas Diganósticas SURA, Antioquia, Colombia; (2) Ayudas Diagnósticas SURA; (3) Ayudas diagnósticas SURA.

PO5-27-12 TALL CELL CARCINOMA WITH REVERSED POLARITY: A RARE SUBTYPE OF INVASIVE BREAST CARCINOMA WITH UNUSUAL ONCOGENIC DRIVER MUTATION R132C IN IDH1 GENE. Karla Prigenzi (1) Luiz Gustavo Ferreira Cortes (1) Paulo Vidal Campregher (1) João Bosco de Oliveira Filho (1) Nestor Andrade Piva (2) (1) Hospital Israelita Albert Einstein; (2) Universidade Federal de São Paulo.

PO5-28-01 Dynamics of Adipocyte Progenitors in the Mammary Gland during Obesity. Sharon Kwende (1) Prashant Nuthalapati (1) Dun Ning (1) Jacqueline Sunder Singh (1) Purna Joshi (1) (1) The University of Texas at Dallas.